View Future GrowthCronos Group 과거 순이익 실적과거 기준 점검 0/6Cronos Group은 연평균 58.9%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 연평균 23.4%의 비율로 증가했습니다. 매출은 연평균 18.2%의 비율로 증가했습니다.핵심 정보58.87%순이익 성장률59.71%주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률23.06%매출 성장률18.24%자기자본이익률0.45%순이익률-1.14%최근 순이익 업데이트31 Mar 2026최근 과거 실적 업데이트Reported Earnings • May 12First quarter 2026 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2026 results: EPS: US$0.037 (up from US$0.016 in 1Q 2025). Revenue: US$45.2m (up 40% from 1Q 2025). Net income: US$13.8m (up 125% from 1Q 2025). Profit margin: 30% (up from 19% in 1Q 2025). Revenue exceeded analyst estimates by 7.5%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 5.0% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 97% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.Reported Earnings • Feb 27Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2025 results: US$0.02 loss per share (down from US$0.11 profit in FY 2024). Revenue: US$146.6m (up 25% from FY 2024). Net loss: US$9.45m (down 123% from profit in FY 2024). Revenue exceeded analyst estimates by 5.1%. Earnings per share (EPS) missed analyst estimates. Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 96% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.Reported Earnings • Nov 06Third quarter 2025 earnings released: EPS: US$0.07 (vs US$0.022 in 3Q 2024)Third quarter 2025 results: EPS: US$0.07 (up from US$0.022 in 3Q 2024). Revenue: US$36.3m (up 6.1% from 3Q 2024). Net income: US$26.0m (up 211% from 3Q 2024). Profit margin: 71% (up from 24% in 3Q 2024). Revenue is forecast to grow 5.8% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 96% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 08Second quarter 2025 earnings: EPS misses analyst expectationsSecond quarter 2025 results: US$0.10 loss per share (further deteriorated from US$0.023 loss in 2Q 2024). Revenue: US$33.5m (up 21% from 2Q 2024). Net loss: US$39.7m (loss widened 354% from 2Q 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates. Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 80% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.Reported Earnings • May 09First quarter 2025 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2025 results: EPS: US$0.02 (up from US$0.006 loss in 1Q 2024). Revenue: US$32.3m (up 28% from 1Q 2024). Net income: US$6.12m (up US$8.36m from 1Q 2024). Profit margin: 19% (up from net loss in 1Q 2024). Revenue exceeded analyst estimates by 2.3%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 9.8% p.a. on average during the next 3 years, compared to a 9.2% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 76% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.Reported Earnings • Feb 28Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2024 results: EPS: US$0.11 (up from US$0.18 loss in FY 2023). Revenue: US$117.6m (up 35% from FY 2023). Net income: US$41.1m (up US$110.9m from FY 2023). Profit margin: 35% (up from net loss in FY 2023). Revenue missed analyst estimates by 2.0%. Earnings per share (EPS) exceeded analyst estimates. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.모든 업데이트 보기Recent updates속보 • May 18Cronos Group Beats Q1 Forecasts With Global Growth and Announces $50 Million BuybackCronos Group reported first-quarter revenue and Adjusted EBITDA ahead of expectations, supported by strong international momentum and Canadian market share gains. The company’s Israeli operations reached a ninth consecutive quarter of record revenue, while its Spinach brand took the number one position in the Canadian vape market. Management authorized a new $50 million share buyback program, and one covering analyst maintained a Buy rating with a C$5.00 price target. The key takeaway is that Cronos is pairing operating progress in core markets like Israel and Canada with capital allocation moves such as buybacks. Together, these developments indicate a focus on both growth and shareholder returns. Investors should still weigh execution risks in international markets and the usual uncertainties around cannabis regulation when assessing how durable these trends may be.Reported Earnings • May 12First quarter 2026 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2026 results: EPS: US$0.037 (up from US$0.016 in 1Q 2025). Revenue: US$45.2m (up 40% from 1Q 2025). Net income: US$13.8m (up 125% from 1Q 2025). Profit margin: 30% (up from 19% in 1Q 2025). Revenue exceeded analyst estimates by 7.5%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 5.0% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 97% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.내러티브 업데이트 • May 12CRON: Partial Rescheduling And Brand Execution Will Shape Lean Profit OutlookAnalysts have lifted their fair value estimate for Cronos Group from CA$3.19 to CA$3.45, citing recent initiation with a CA$4.50 price target and the view that branded positioning, a lean cost base, and potentially favorable regulatory shifts could support higher long term profitability and a lower future P/E assumption. Analyst Commentary Recent commentary around Cronos Group has focused on brand strength, cost discipline, and the potential impact of regulatory changes in key markets.공시 • May 08Cronos Group Inc. Expands Pre-Roll Portfolio With Spinach STIXCronos Group Inc. announced that Spinach STIX, its latest innovation in its popular line-up of Spinach pre-rolls, is now available in more provinces across Canada. Spinach STIX is the brand’s first cylindrical-style pre-roll, designed to meet surging consumer interest in this highly sought-after format in the pre-roll category. The pre-roll category remains one of the largest and most popular in the Canadian cannabis market, accounting for more than 33% of national retail dollar sales. Nationally, the demand for cylindrical-style pre-rolls, which represented more than $17 million in Canadian retail sales in the pre-roll category in March 2026, is driven by consumer demand for pre-rolls that deliver a portable and compact design, an even and consistent burn, and a balanced, smooth smoking experience. Spinach STIX are available in the following curated selection of Cronos’ top-performing strains: Spinach STIX GMO Cookies, featuring sweet and savory flavor notes, Indica, THC: 25%+, 10x0.4g; Spinach STIX Sour Chem, featuring classic gasoline, chemical, and zesty citrus notes, Sativa, THC: 26%+, 10x0.4g; Spinach STIX Space Cake, featuring berry, nutty, and citrusy flavors, Hybrid, THC: 24%+, 10x0.4g. Spinach STIX pre-rolls are available now in Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland, Nova Scotia, Ontario, and Saskatchewan.내러티브 업데이트 • Apr 25CRON: Partial Rescheduling Hopes Will Test Lean Cost Base ExecutionAnalysts have raised their Cronos Group price target to CA$4.50, citing expectations for slightly stronger revenue growth, modestly better profit margins, and a lower assumed future P/E, following recent bullish coverage and a favorable view on partial cannabis rescheduling. Analyst Commentary Recent research coverage on Cronos Group has centered on how potential regulatory shifts and brand positioning could influence the company’s path to improved profitability and valuation.내러티브 업데이트 • Apr 11CRON: Canadian Brand Strength And Lean Cost Base Will Support Future UpsideAnalysts have reset their price target for Cronos Group to CA$4.50, reflecting fresh coverage that highlights the company’s established Canadian brands, its focus on scaling revenue with a lean cost base, and cultivation practices that are expected to support profitability trends. Analyst Commentary Recent coverage frames Cronos Group as a company with established Canadian brands and a focus on keeping its cost base lean while scaling revenue.공시 • Mar 30Cronos Group Inc., Annual General Meeting, Jun 18, 2026Cronos Group Inc., Annual General Meeting, Jun 18, 2026.내러티브 업데이트 • Mar 28CRON: Lean Cost Base And Brand Execution Will Shape Future Earnings PotentialAnalysts have lifted their average price target for Cronos Group to CA$4.50, citing expectations for faster top line expansion, a leaner cost base and stronger profitability potential supported by the company's established Canadian cannabis brands and cultivation practices. Analyst Commentary Recent Street research has framed Cronos Group as a branded cannabis operator with established products in Canada and an emphasis on scaling revenue while keeping operating costs in check.내러티브 업데이트 • Mar 13CRON: Canadian Brand Strength And Rescheduling Shift Will Support Future UpsideAnalysts have lifted their CA$ price target on Cronos Group, citing the company's Canadian cannabis brands, expectations for better profitability as revenue grows against a lean cost base, and confidence in its cultivation practices as key supports for the higher valuation range. Analyst Commentary Bullish Takeaways Bullish analysts highlight Cronos Group's portfolio of Canadian cannabis brands as a key support for the higher CA$ valuation range, arguing that strong consumer recognition can help sustain revenue as the company scales.Recent Insider Transactions Derivative • Mar 12President exercised options and sold CA$451k worth of stockOn the 8th of March, Michael Gorenstein exercised options to acquire 129k shares at no cost and sold these for an average price of CA$3.50 per share. This trade did not impact their existing holding. For the year to December 2019, Michael's total compensation was 19% salary and 81% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2025, Michael's direct individual holding has increased from 12.51m shares to 12.81m. Company insiders have collectively sold CA$4.7m more than they bought, via options and on-market transactions in the last 12 months.Reported Earnings • Feb 27Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2025 results: US$0.02 loss per share (down from US$0.11 profit in FY 2024). Revenue: US$146.6m (up 25% from FY 2024). Net loss: US$9.45m (down 123% from profit in FY 2024). Revenue exceeded analyst estimates by 5.1%. Earnings per share (EPS) missed analyst estimates. Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 96% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.내러티브 업데이트 • Feb 27CRON: Canadian Brand Strength And Rescheduling Shift Will Reshape Risk Reward ProfileAnalysts have lifted their fair value estimate for Cronos Group to CA$4.24 from CA$3.95, pointing to higher assumed revenue growth and a lower future P/E multiple. They are factoring in recent bullish coverage highlighting the company’s established Canadian cannabis brands, lean cost base, and cultivation practices.Price Target Changed • Feb 24Price target increased by 7.2% to CA$4.24Up from CA$3.95, the current price target is an average from 4 analysts. New target price is 13% above last closing price of CA$3.74. Stock is up 39% over the past year. The company is forecast to post a net loss per share of US$0.0034 compared to earnings per share of US$0.11 last year.공시 • Feb 17Cronos Group Inc. Launches New All-In-One Vape, Spinach PUFFERZCronos Group Inc. announced the launch of its newest all-in-one (AIO) vape, Spinach PUFFERZ. The latest innovation under Cronos' Spinach®? brand brings together high-quality cannabis infused with liquid diamonds in a convenient all-in-one device. Crafted for modern cannabis consumers who value functionality and design, Spinach PUFFERZ™? offers a seamless way to enjoy high-quality cannabis vape extracts and bold flavors. Every design element was carefully considered to deliver a differentiated experience. Spinach PUafferZ™? is Cronos' first AIO vape featuring the increasingly popular palm-style hardware. The device boasts a uniquely satisfying squish grip with a puffy exterior, a dual ceramic coil for maximum flavor and smooth draws, a boost button for temperature control, and a battery meter to indicate when a charge is needed. Spinach PUFFERZ™, the.내러티브 업데이트 • Feb 13CRON: Rescheduling Shift Will Expose Execution Risks And Restrain Earnings UpsideAnalysts have lifted their CA$ fair value estimate for Cronos Group to CA$3.19, citing Street research that points to slightly higher expected revenue growth, modestly stronger profit margins, and a marginally lower future P/E assumption that together support a more constructive long term outlook. Analyst Commentary While the higher CA$3.19 fair value estimate reflects a more constructive stance on Cronos Group, not all research is leaning in the same direction.공시 • Feb 03Cronos Group Launches Premium Lord Jones Brand in Israel, Advancing Borderless Product StrategyCronos Group Inc. announced the launch of its Lord Jones premium cannabis brand in Israel. The introduction marks a significant milestone in Cronos' borderless product strategy, expanding the Company's globally recognized brand portfolio into one of the most advanced and discerning medical cannabis markets in the world. The first phase of the launch brings five premium indoor-grown flower strains to Israeli patients. Lord Jones, established in North America for its refined brand identity and elevated craftsmanship, now enters the Israeli medical market with a focus on meeting the needs of medical patients. The brand's expansion into Israel underscores Cronos' commitment to thoughtful international growth driven by disciplined execution and differentiated brand experiences. In addition to the core flower offering, Cronos plans to expand the Lord Jones brand in Israel with future special edition and limited-run products. Lord Jones products are now available in pharmacies across Israel.내러티브 업데이트 • Jan 30CRON: Rescheduling Shift And Product Expansion Will Shape A Balanced Earnings OutlookAnalysts have raised their price target on Cronos Group by a small amount to reflect updated assumptions for slightly higher revenue growth, a modestly stronger profit margin, and a marginally higher future P/E multiple. Analyst Commentary While some research points to a constructive view on Cronos Group, bearish analysts highlight a set of risks that could limit upside and keep the stock more range bound.Major Estimate Revision • Jan 16Consensus EPS estimates fall from profit to US$0.005 lossThe consensus outlook for fiscal year 2025 has been updated. Expected to report loss instead of -US$0.005 instead of US$0.0205 per share profit previously forecast. Revenue forecast unchanged at US$137.9m Pharmaceuticals industry in Canada expected to see average net income growth of 40% next year. Consensus price target up from CA$3.95 to CA$4.10. Share price fell 5.4% to CA$3.53 over the past week.내러티브 업데이트 • Jan 16CRON: Rescheduling Policy Shift Will Temper Optimism On Future Earnings ProfileAnalysts have raised their price target for Cronos Group to US$3.19 from US$2.90, pointing to updated assumptions around slightly higher discount rates, more conservative revenue growth and a modestly stronger profit margin profile, alongside a similar forward P/E outlook. What's in the News President Trump directed the Attorney General to complete the rulemaking process to reschedule marijuana to Schedule III of the Controlled Substances Act, which directly touches U.S. cannabis policy and mentions Cronos Group among other publicly traded peers in the sector (Marijuana Herald).Recent Insider Transactions Derivative • Dec 17President exercised options and sold CA$293k worth of stockOn the 13th of December, Michael Gorenstein exercised options to acquire 65k shares at no cost and sold these for an average price of CA$4.51 per share. This trade did not impact their existing holding. For the year to December 2018, Michael's total compensation was 19% salary and 81% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2025, Michael has owned 12.51m shares directly. Company insiders have collectively sold CA$4.5m more than they bought, via options and on-market transactions in the last 12 months.분석 기사 • Dec 13Cronos Group Inc. (TSE:CRON) Stock Rockets 29% As Investors Are Less Pessimistic Than ExpectedCronos Group Inc. ( TSE:CRON ) shareholders have had their patience rewarded with a 29% share price jump in the last...Valuation Update With 7 Day Price Move • Dec 12Investor sentiment improves as stock rises 29%After last week's 29% share price gain to CA$4.48, the stock trades at a forward P/E ratio of 50x. Average trailing P/E is 14x in the Pharmaceuticals industry in Canada. Total returns to shareholders of 15% over the past three years.공시 • Dec 10Cronos Group Inc. (TSX:CRON) entered into a definitive share sale and purchase agreement to acquire CanAdelaar B.V. from Ring International Holding AG and Landewyck Tobacco S.A.Cronos Group Inc. (TSX:CRON) entered into a definitive share sale and purchase agreement to acquire CanAdelaar B.V. from Ring International Holding AG and Landewyck Tobacco S.A. on December 9, 2025. The total consideration for the transaction is structured as follows: The base amount is €57.5 million. This amount will be adjusted by the net indebtedness, where a positive cash balance will increase the total, and a negative sum will decrease it. Additionally, €0.13 million, referred to as the "Sellers W&I Premium Amount," will be subtracted. Furthermore, 50% of any additional underwriting fees incurred by the purchaser up to completion, specifically related to additional due diligence aimed at lifting certain exclusions currently included in the W&I Policy, will be added to the total consideration. The consideration includes an additional contingent payment, payable in cash, based on 0.5 times CanAdelaar’s normalized EBITDA for the years 2026 and 2027. For the period ending September 30, 2025, CanAdelaar B.V. reported total revenue of €40.34 million and EBITDA of €24.05 million. The transaction is subject to approval by regulatory board / committee and approval of offer by acquirer board. The deal has been unanimously approved by the board. The expected completion of the transaction is January 1, 2026 to June 30, 2026.공시 • Nov 25Cronos Group Inc. Launches Premium Lord Jones Live Resin Fusions in CanadaCronos Group Inc. announced is expanding its portfolio for its Lord Jones®? brand with new innovations designed to enhance its lineup of premium cannabis products in the Canadian market. The new Lord Jones Live Resin Fusions™? pre-rolls combine top-tier craftsmanship with exceptional cannabis genetics, reflecting the brand's continued dedication to quality and refinement. The Lord Jones Live Resin Fusion™? are carefully curated, pairing single-sourced dried flower with complementary, terpene-rich pure live resin caviar to deliver a delicious, flavor-forward, and differentiated smoking experience. Designed with an optimal ratio of live resin caviar-to-flower, each 0.5g pre-roll ensures a consistently smooth burn and high potency of 42%+ THC. Every pre-roll is fitted with a reusable ceramic tip, which cools the smoke for an even smoother, elevated experience. The Lord Jones Live Res in Fusions are now available in the following new strains: Lord Jones Live Resin F Fusion™? Durban Kush x Citrus Sap; Lord Jones Live Resin F intr™? Hell Fire OG x Cali Gas; Lord Jones Live ResinFusions™? Sour Diesel X Orange Velvet. New Lord Jones Live Resin F infusion™? are now available at select retailers across Canada.Reported Earnings • Nov 06Third quarter 2025 earnings released: EPS: US$0.07 (vs US$0.022 in 3Q 2024)Third quarter 2025 results: EPS: US$0.07 (up from US$0.022 in 3Q 2024). Revenue: US$36.3m (up 6.1% from 3Q 2024). Net income: US$26.0m (up 211% from 3Q 2024). Profit margin: 71% (up from 24% in 3Q 2024). Revenue is forecast to grow 5.8% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 96% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.공시 • Oct 28Cronos Group Inc. Brings Back Popular, Limited-Edition Spinach Green Apple-Flavored Products for the Fall SeasonCronos Group Inc. announced that it is welcoming back its limited-edition Caramel Green Apple flavor to its best-selling lineup of SOURZ by Spinach edibles for the fall and Halloween season. The return of this popular and limited-edition product, which features buttery, sweet caramel and tart-green apple flavors and is perfect for the autumn months, follows its successful launch in Fall 2024. In addition to bringing back the original SOURZ by Spinach Caramel Green Apple 5-pack of gummies, Cronos is expanding its Fall season exclusive offerings with two new products: SOURZ by Spinach Fully Blasted Caramel Green Apple 10mg THC gummy; Spinach Sweet Green Apple 1g vape (Sativa): Infused with liquid diamonds and featuring crisp green apple flavor notes. These limited-time, seasonal Spinach products are available now across Canada.공시 • Oct 09Cronos Group Inc. Launches Sourz by Spinach Fully Blasted MultipacksCronos Group Inc. announced that its popular SOURZ by Spinach Fully Blasted gummies will now be available in new multipack formats. The SOURZ by Spinach fully Blasted Multipacks with liquid diamond-infused gummies are now available in five of its most popular flavors, offering consumers more choice, convenience, and value when purchasing Canada's favorite cannabis edible. SOURZ by Spinach Fully Blasted Multipacks with Liquid diamond-infused gummies will be available in 5- and 10-packs in the following flavors: 10-Pack (10 x 10mg THC gummies): SOURZ by Spinach Fully Blasted Blue Raspberry Watermelon gummies; SOURZ by Spinach Fully Blasted Pink Lemonade gummies; SOUR Z by Spinach FullyBlasted Strawberry Mango gummies: SOURZ by spinach Fully Blasted Peach Orange gummies; 5-Pack (5 x 10mg THC gummies); SOURZ by Spinach- Fully Blasted Blue Raspberry Water Watermelon gummies; SourZ by Spinach fully Blasted Pink Lemonade gibles; SOURZ by SpinACH Fully Blasted Strawberry Mango gummies; SOURZ By Spinach Fully Blasting Peach Orange gummies; 5 -Pack (5 x 10mgTH gummies); SOURZ By Spinach Fully Blasting Peach Orange Gummies; 5-Pack (5 x 10mg THC gummies; SOURZby Spinach Fully Blast Blue Raspberry Watermelon gummies and SOURZ by Spinach? Fully Blasted Pink Lemonades gummies. The SOURZ by spinach Fully Blasted Multipack with liquid diamond-infused Gummies are available now in Alberta, British Columbia, Manitoba, Newfoundland, Nova Scotia, Ontario, Prince Edward Island, and Saskatchewan.Valuation Update With 7 Day Price Move • Sep 29Investor sentiment improves as stock rises 16%After last week's 16% share price gain to CA$4.13, the stock trades at a forward P/E ratio of 109x. Average trailing P/E is 34x in the Pharmaceuticals industry in Canada. Total returns to shareholders of 3.0% over the past three years.내러티브 업데이트 • Sep 04GrowCo Capacity And Global Markets Will Unlock PotentialThe Consensus Analyst Price Target for Cronos Group has increased to CA$3.95, primarily reflecting a notable rise in the company's Future P/E multiple despite stable revenue growth expectations. What's in the News President Trump is considering reclassifying marijuana as a less dangerous drug, which could ease restrictions and benefit cannabis companies such as Cronos Group (The Wall Street Journal).Price Target Changed • Sep 03Price target increased by 10% to CA$3.95Up from CA$3.59, the current price target is an average from 2 analysts. New target price is 14% above last closing price of CA$3.48. Stock is up 17% over the past year. The company is forecast to post a net loss per share of US$0.015 compared to earnings per share of US$0.11 last year.분석 기사 • Aug 15Cronos Group Inc.'s (TSE:CRON) 26% Share Price Surge Not Quite Adding UpCronos Group Inc. ( TSE:CRON ) shareholders would be excited to see that the share price has had a great month, posting...Reported Earnings • Aug 08Second quarter 2025 earnings: EPS misses analyst expectationsSecond quarter 2025 results: US$0.10 loss per share (further deteriorated from US$0.023 loss in 2Q 2024). Revenue: US$33.5m (up 21% from 2Q 2024). Net loss: US$39.7m (loss widened 354% from 2Q 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates. Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 80% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.공시 • Aug 07Cronos Group Inc. Appoints Lloyd Wilson as the Principal Accounting Officer, Effective as of August 7, 2025Cronos Group Inc. Appointed Lloyd Wilson, Vice President, Controller, as the Company’s principal accounting officer, effective as of August 7, 2025. Lloyd is a seasoned financial leader and licensed Chartered Public Accountant with over 20 years of experience in financial reporting, internal audit, plant controllership, and operational finance. With a strong background in consumer-packaged goods and previous experience as a plant controller, Lloyd most recently served as a Corporate Controller, where he oversaw financial reporting, internal controls, and policy implementation.Price Target Changed • Jul 09Price target increased by 14% to CA$4.08Up from CA$3.59, the current price target is an average from 3 analysts. New target price is 43% above last closing price of CA$2.85. Stock is down 9.2% over the past year. The company is forecast to post a net loss per share of US$0.061 compared to earnings per share of US$0.11 last year.Major Estimate Revision • Jul 02Consensus EPS estimates fall by 254%, revenue upgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast increased from US$146.6m to US$149.5m. Forecast EPS reduced from -US$0.017 to -US$0.061 per share. Pharmaceuticals industry in Canada expected to see average net income growth of 34% next year. Consensus price target of CA$3.77 unchanged from last update. Share price was steady at CA$2.61 over the past week.Major Estimate Revision • May 15Consensus EPS estimates have been downgraded.The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from US$149.2m to US$145.5m. Now expected to report a loss of US$0.006 per share instead of US$0.0074 per share profit previously forecast. Pharmaceuticals industry in Canada expected to see average net income growth of 38% next year. Consensus price target of CA$3.48 unchanged from last update. Share price rose 5.0% to CA$2.92 over the past week.Reported Earnings • May 09First quarter 2025 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2025 results: EPS: US$0.02 (up from US$0.006 loss in 1Q 2024). Revenue: US$32.3m (up 28% from 1Q 2024). Net income: US$6.12m (up US$8.36m from 1Q 2024). Profit margin: 19% (up from net loss in 1Q 2024). Revenue exceeded analyst estimates by 2.3%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 9.8% p.a. on average during the next 3 years, compared to a 9.2% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 76% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.공시 • May 09Cronos Group Inc. (TSX:CRON) announces an Equity Buyback for 19,270,951 shares, representing 5% for $50 million.Cronos Group Inc. (TSX:CRON) announces a share repurchase program. Under the program, the company will repurchase up to 19,270,951 shares representing 5% of it's issued share for $50 million. The repurchases will be made from available funds. The repurchase program is valid till May 13, 2026.새로운 내러티브 • Apr 30GrowCo Expansion Will Boost Operations But Strain Cash Flow Investment in GrowCo and advancements in cannabis genetics are set to improve efficiency, enhance profitability, and strengthen market penetration. 공시 • Apr 23Cronos Group Inc. Unveils New Spinach 1.2g Vapes and SOURZ by Spinach Gummies Enhanced with Rare CannabinoidsCronos Group Inc.'s best-selling cannabis brand, Spinach®?, introduced three all-new 1.2g vape products, each expertly crafted with premium THC and enhanced with rare cannabinoids for a uniquely elevated experience. Along with these innovative vape offerings, Cronos is also unveiling new SOURZ by Spinach®? Fully Blasted flavors, infused with rare cannabinoids. The new lineup includes three new 1.2 gram vapes in the following formats: Mango Kiwi Haze CBC (Sativa): A refreshing, uplifting blend with a 1:10 CBC-to-THC ratio. Peach Passionfruit Kush CBN (Indica): A dreamy, restful experience with a 1:10 CBN-to-THC ratio; Strawberry Watermelon OG CBG (Hybrid): A blissful, relaxed high with a 1:10 CBG-to-THC ratio.; Designed for consumers who prioritize both potency and added value, these vapes deliver 1,000mg of THC without compromising on the unique benefits of rare cannabinoids. Each product features winterized, distilled cannabis extract for purity, combined with terpene-rich flavors inspired by renowned cultivars. All Spinach®? vapes are crafted with ceramic heaters, stainless steel components, and food-grade materials to ensure quality and a smooth experience. In addition to the Spinach®? vape launch, Cronos is expanding its best-selling edible line, SOURZ by Spinach™?, with the new Fully Blasted lineup with each package containing one 10mg THC gummy in bold, fruit-forward flavors: Mango Lime: Tropical mango and tangy lime flavors with 10mg CBC and 10mg THC per gummy.공시 • Mar 28Cronos Group Inc., Annual General Meeting, Jun 20, 2025Cronos Group Inc., Annual General Meeting, Jun 20, 2025.Recent Insider Transactions Derivative • Mar 26President exercised options and sold CA$3.1m worth of stockOn the 21st of March, Michael Gorenstein exercised options to acquire 1m shares at no cost and sold these for an average price of CA$2.61 per share. This trade did not impact their existing holding. For the year to December 2018, Michael's total compensation was 21% salary and 79% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2024, Michael's direct individual holding has increased from 11.09m shares to 11.68m. Company insiders have collectively sold CA$4.4m more than they bought, via options and on-market transactions in the last 12 months.공시 • Mar 20Cronos Group Inc. Announces Chief Financial Officer ChangesCronos Group Inc. announced the appointment of Anna Shlimak as Chief Financial Officer, effective March 19, 2025. Ms. Shlimak, who previously served as Cronos’ Chief Strategy Officer, will succeed James Holm who is stepping down to pursue other opportunities and will remain with the Company through April 18, 2025 to ensure a seamless transition. Ms. Shlimak has been an integral part of Cronos’ leadership team for the last seven years, playing a key role in shaping the Company’s strategy, operational efficiencies, and engagement with the financial and investment community. During her tenure, she has led many strategic initiatives including cost optimization, revenue growth, and building Cronos’ corporate brand, which have positioned the Company for long-term success. Anna recently served as the Company’s Chief Strategy Officer and was responsible for managing and directing the organization’s corporate strategy, investor relations, communications, government affairs, and information systems departments. Prior to joining Cronos, Anna was the Head of Investor Relations at Quest Partners LLC, a research-driven alternative investment firm. Anna was responsible for business development, investor reporting, marketing, and communication initiatives for the fund. Before that, Anna held a range of roles at the New York Stock Exchange in both the New York and London offices. She received a Master of Business Administration from Columbia Business School and holds a Bachelor of Science in Economics from The Wharton School at the University of Pennsylvania.Recent Insider Transactions Derivative • Mar 19President exercised options and sold CA$306k worth of stockOn the 15th of March, Michael Gorenstein exercised options to acquire 112k shares at no cost and sold these for an average price of CA$2.72 per share. This trade did not impact their existing holding. For the year to December 2018, Michael's total compensation was 21% salary and 79% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2024, Michael's direct individual holding has decreased from 11.09m shares to 10.45m. Company insiders have collectively sold CA$1.3m more than they bought, via options and on-market transactions in the last 12 months.Recent Insider Transactions Derivative • Mar 12President exercised options and sold CA$230k worth of stockOn the 8th of March, Michael Gorenstein exercised options to acquire 80k shares at no cost and sold these for an average price of CA$2.86 per share. This trade did not impact their existing holding. For the year to December 2018, Michael's total compensation was 21% salary and 79% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2024, Michael's direct individual holding has decreased from 11.09m shares to 10.20m. Company insiders have collectively sold CA$1.2m more than they bought, via options and on-market transactions in the last 12 months.Reported Earnings • Feb 28Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2024 results: EPS: US$0.11 (up from US$0.18 loss in FY 2023). Revenue: US$117.6m (up 35% from FY 2023). Net income: US$41.1m (up US$110.9m from FY 2023). Profit margin: 35% (up from net loss in FY 2023). Revenue missed analyst estimates by 2.0%. Earnings per share (EPS) exceeded analyst estimates. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.Recent Insider Transactions Derivative • Dec 17President exercised options and sold CA$183k worth of stockOn the 13th of December, Michael Gorenstein exercised options to acquire 66k shares at no cost and sold these for an average price of CA$2.79 per share. This trade did not impact their existing holding. For the year to December 2017, Michael's total compensation was 21% salary and 79% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2024, Michael has owned 11.09m shares directly. Company insiders have collectively sold CA$826k more than they bought, via options and on-market transactions in the last 12 months.Breakeven Date Change • Dec 05Forecast to breakeven in 2025The 3 analysts covering Cronos Group expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 82% to 2024. The company is expected to make a profit of US$10.2m in 2025. Average annual earnings growth of 95% is required to achieve expected profit on schedule.Reported Earnings • Nov 14Third quarter 2024 earnings: EPS and revenues exceed analyst expectationsThird quarter 2024 results: EPS: US$0.02 (up from US$0.004 loss in 3Q 2023). Revenue: US$34.3m (up 38% from 3Q 2023). Net income: US$8.35m (up US$9.81m from 3Q 2023). Profit margin: 24% (up from net loss in 3Q 2023). Revenue exceeded analyst estimates by 13%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 3.6% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.Major Estimate Revision • Nov 13Consensus revenue estimates increase by 12%, EPS downgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast increased from US$107.8m to US$120.7m. EPS estimate fell from -US$0.072 to -US$0.086 per share. Pharmaceuticals industry in Canada expected to see average net income growth of 51% next year. Consensus price target of CA$3.44 unchanged from last update. Share price was steady at CA$3.15 over the past week.Major Estimate Revision • Oct 01Consensus EPS estimates upgraded to US$0.074 lossThe consensus outlook for fiscal year 2024 has been updated. 2024 losses forecast to reduce from -US$0.083 to -US$0.074 per share. Revenue forecast unchanged from US$111.3m at last update. Pharmaceuticals industry in Canada expected to see average net income growth of 55% next year. Consensus price target of CA$3.51 unchanged from last update. Share price was steady at CA$2.87 over the past week.공시 • Aug 28Cronos Group Inc. Announces Lord Jones Live Resin Vapes and Ice Water Hash Pre-Rolls Now Available Across CanadaCronos Group Inc. is expanding its portfolio for its Lord Jones brand with new innovations to bolster its lineup of premium cannabis products in the Canadian market. The additions include new cultivars for the Lord Jones Ice Water Hash Fusions Pre-Rolls and Live Resin Vapes, which are now available across Canada. The Lord Jones Ice Water Hash Fusions Pre-Rolls and Live Resin Vapes are now available in the following new flavors and sizes: Lord Jones Ice Water Hash Fusions Pre-Rolls: Sour Blueberry x Sour Blueberry. 1g ice water hash flower pre-roll with blueberry and gas flavor notes. Indica | THC: 35-41% | 1x1g. Snow Lotus x Animal Mints. 1g ice water hash flower pre-roll with sweet, minty, and spicy flavor notes. Hybrid | THC: 35-41% | 1x1g Lord Jones Live Resin Vapes (All-in-One and 510-Cartridge): Gorilla Z Live Resin Vape A flavor-forward vape designed to boast an promoted berry, cherry, and grape flavor experience. Hybrid | 70+% THC . Available in two hardware options that are optimized for live resin usage: A sleek 0.5g all-in-one device. A high-quality 1g 510-thread cartridge.Breakeven Date Change • Aug 12No longer forecast to breakevenThe 7 analysts covering Cronos Group no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$1.46m in 2025. New consensus forecast suggests the company will make a loss of US$6.32m in 2026.Reported Earnings • Aug 09Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behindSecond quarter 2024 results: US$0.02 loss per share (further deteriorated from US$0.015 loss in 2Q 2023). Revenue: US$27.8m (up 46% from 2Q 2023). Net loss: US$8.76m (loss widened 59% from 2Q 2023). Revenue exceeded analyst estimates by 7.2%. Earnings per share (EPS) missed analyst estimates. Revenue is forecast to grow 7.2% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.Major Estimate Revision • Jul 12Consensus EPS estimates fall by 10%The consensus outlook for fiscal year 2024 has been updated. 2024 expected loss increased from -US$0.042 to -US$0.046 per share. Revenue forecast unchanged at US$103.7m. Pharmaceuticals industry in Canada expected to see average net income growth of 54% next year. Consensus price target of CA$3.61 unchanged from last update. Share price rose 6.5% to CA$3.26 over the past week.Breakeven Date Change • Jul 11No longer forecast to breakevenThe 7 analysts covering Cronos Group no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$5.69m in 2025. New consensus forecast suggests the company will make a loss of US$6.12m in 2026.Major Estimate Revision • Jul 01Consensus EPS estimates fall by 93%The consensus outlook for fiscal year 2024 has been updated. 2024 expected loss increased from -US$0.022 to -US$0.042 per share. Revenue forecast of US$103.3m unchanged since last update. Pharmaceuticals industry in Canada expected to see average net income growth of 56% next year. Consensus price target down from CA$3.74 to CA$3.61. Share price was steady at CA$3.19 over the past week.공시 • Jun 28Cronos Group Inc. Brand Spinach®? Celebrates Summer with New LaunchesCronos Group Inc.'s Spinach®? brand is expanding its portfolio of award-winning and best-selling cannabis products just in time for the summer months. Summer innovations feature new flavors and formats from Cronos' SOURZ by Spinach®? edibles and a premier milled flower product. The new SOURZ by Spinach™? Fully Blasted gummies offer the same great-tasting SOURZ by Spinach ®? flavors, now with 10 mg of THC per piece. The SOURZ by SpinACH®? Tropical Party Pack introduces new gummies with bolder tropical flavors, in the distinctive Spinach®? "S" shape. These gummies have a perfect blend of sour and sweet and utilize Cronos' proprietary flavor-masking technology. SOURZ by SpinachTM Fully Blasted includes one 10 mg THC gummy per package in the following flavors: Pink Lemonade; Sweet and refreshing flavors of raspberry and lemonade; Blue Raspberry Watermelon; Electric blue raspberry and refreshing watermelon; Cherry Lime; Delightful cherry and tangy lime. SOURZ by SpinACH™? Tropical Party Pack: 1 mg THC per gummy, 10 mg THC per pack; Featuring three new dual-flavors: Peach Passionfruit, Pineapple Coconut, and Strawberry Guava. Additionally, the Spinach®? brand will introduce Spinach®?, milled flower options designed to be ready to use for joints or vaporizers. Ready-to-use milled flower offerings have grown in popularity in the Canadian cannabis market, appealing to value-conscious consumers seeking convenience. Spinach Grindz™? caters to this growing demand by providing high-quality, milled cannabis that saves time and effort, allowing consumers to enjoy a consistent and hassle-free cannabis experience. Spinach Grindz®? are now available in the following strains: Citrus Crush; Milled flower with citrus, sour, and earthy notes; Cookie Dough; Milled flower with sweet, nutty, and creamy notes.공시 • Jun 22Cronos Group Inc. Elects Murray Garnick as DirectorCronos Group Inc. at its Annual Meeting of Shareholders held on June 20, 2024, approved to elect Murray Garnick as director.분석 기사 • May 31We're Interested To See How Cronos Group (TSE:CRON) Uses Its Cash Hoard To GrowEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Breakeven Date Change • May 12Forecast breakeven date moved forward to 2025The 8 analysts covering Cronos Group previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 87% to 2024. The company is expected to make a profit of US$5.67m in 2025. Average annual earnings growth of 62% is required to achieve expected profit on schedule.Reported Earnings • May 10First quarter 2024 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2024 results: US$0.01 loss per share (improved from US$0.05 loss in 1Q 2023). Revenue: US$25.3m (up 26% from 1Q 2023). Net loss: US$2.24m (loss narrowed 88% from 1Q 2023). Revenue exceeded analyst estimates by 7.0%. Earnings per share (EPS) also surpassed analyst estimates by 1.9%. Revenue is forecast to grow 8.7% p.a. on average during the next 3 years, compared to a 9.1% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.Major Estimate Revision • May 07Consensus EPS estimates upgraded to US$0.036 lossThe consensus outlook for fiscal year 2024 has been updated. 2024 losses forecast to reduce from -US$0.045 to -US$0.036 per share. Revenue forecast steady at US$99.8m. Pharmaceuticals industry in Canada expected to see average net income growth of 49% next year. Consensus price target of CA$3.57 unchanged from last update. Share price fell 10% to CA$3.63 over the past week.Breakeven Date Change • May 07No longer forecast to breakevenThe 7 analysts covering Cronos Group no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$1.72m in 2026. New consensus forecast suggests the company will make a loss of US$4.06m in 2026.Major Estimate Revision • Apr 16Consensus EPS estimates fall by 24%The consensus outlook for fiscal year 2024 has been updated. 2024 expected loss increased from -US$0.036 to -US$0.045 per share. Revenue forecast of US$100.9m unchanged since last update. Pharmaceuticals industry in Canada expected to see average net income growth of 50% next year. Consensus price target of CA$3.57 unchanged from last update. Share price fell 7.2% to CA$3.36 over the past week.분석 기사 • Apr 01Cronos Group Inc.'s (TSE:CRON) P/S Is Still On The Mark Following 29% Share Price BounceThe Cronos Group Inc. ( TSE:CRON ) share price has done very well over the last month, posting an excellent gain of...공시 • Mar 28Cronos Group Inc., Annual General Meeting, Jun 20, 2024Cronos Group Inc., Annual General Meeting, Jun 20, 2024.Major Estimate Revision • Mar 26Consensus EPS estimates upgraded to US$0.037 lossThe consensus outlook for fiscal year 2024 has been updated. 2024 losses forecast to reduce from -US$0.046 to -US$0.037 per share. Revenue forecast steady at US$100.9m. Pharmaceuticals industry in Canada expected to see average net income growth of 56% next year. Consensus price target of CA$3.46 unchanged from last update. Share price rose 17% to CA$3.62 over the past week.공시 • Mar 26Cronos Group Inc. Launches Lord Jones Chocolate FusionsCronos Group Inc. announced the launch of Lord Jones Chocolate Fusions, its exciting first entry into the chocolate edibles category. Cronos' newest edible innovation was developed and designed by an expert team of culinary chefs, food scientists, and leaders in cannabis product development. The bite-sized Chocolate Fusions feature a dynamic, multi- texture experience, combining a soft and chewy center, crunch inclusions, and an outer layer of rich creamy chocolate that delivers a decadent sweet treat for adult cannabis consumers. Lord Jones Chocolate Fusions feature winning attributes to attract cannabis consumers, including three delicious flavor combinations, an artisanal design that highlights a creative combination of textures, and a flavor-masking system to ensure outstanding taste. Through an extensive research and sensory testing process, team of experts seized the opportunity to deliver an exceptional edible that elevates the overall category. Each package of Lord Jones Chocolate Fusions includes five pieces with 2mg of THC per piece. Chocolate Fusions will be available in the following flavors and formats: Lord Jones Cookies & Cream Chocolate Fusions, 10mg THC total per package, Three layers of white chocolate, cookie crunch bits, and a chewy fudge center, Lord Jones Salted Caramel Crunch 1:1 CBD | THC Chocolate Fusions, 10mg CBD per package, 10mg THC and 10mg CBD per package, Three layers of milk chocolate, a sweet and salty crunch, and a smooth caramel center, Lord Jones Dazzleberry Pop Chocolate Fusions, 10mgTH total per package, Three layers the gold-dusted dark chocolate, a crackling pop, and a sweet berry center. Cronos continues to be an award-winning leader in cannabis edibles. The same team behind the hugely popular SOURZ by Spinach® and Spinach FEELZTM portfolio of gummies leveraged their expertise in the edibles space to create this innovation for the chocolate category for the Lord Jones® brand.Recent Insider Transactions Derivative • Mar 20President exercised options and sold CA$232k worth of stockOn the 15th of March, Michael Gorenstein exercised options to acquire 87k shares at no cost and sold these for an average price of CA$2.68 per share. This trade did not impact their existing holding. For the year to December 2017, Michael's total compensation was 4% salary and 96% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2023, Michael's direct individual holding has increased from 9.64m shares to 9.83m. Company insiders have collectively sold CA$963k more than they bought, via options and on-market transactions in the last 12 months.Reported Earnings • Mar 03Full year 2023 earnings: EPS and revenues miss analyst expectationsFull year 2023 results: US$0.18 loss per share (improved from US$0.45 loss in FY 2022). Revenue: US$87.2m (down 5.1% from FY 2022). Net loss: US$69.8m (loss narrowed 59% from FY 2022). Revenue missed analyst estimates by 1.6%. Earnings per share (EPS) also missed analyst estimates by 101%. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings.분석 기사 • Mar 02We Think Cronos Group (TSE:CRON) Can Afford To Drive Business GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Major Estimate Revision • Mar 02Consensus EPS estimates fall by 44%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from US$109.2m to US$102.2m. Losses expected to increase from US$0.03 per share to US$0.043. Pharmaceuticals industry in Canada expected to see average net income growth of 63% next year. Consensus price target of CA$3.49 unchanged from last update. Share price fell 9.2% to CA$2.75 over the past week.분석 기사 • Feb 02Revenues Tell The Story For Cronos Group Inc. (TSE:CRON)When you see that almost half of the companies in the Pharmaceuticals industry in Canada have price-to-sales ratios (or...Breakeven Date Change • Dec 31Forecast to breakeven in 2026The 8 analysts covering Cronos Group expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$236.3k in 2026. Average annual earnings growth of 68% is required to achieve expected profit on schedule.Recent Insider Transactions Derivative • Dec 17President exercised options and sold CA$169k worth of stockOn the 13th of December, Michael Gorenstein exercised options to acquire 66k shares at no cost and sold these for an average price of CA$2.58 per share. This trade did not impact their existing holding. For the year to December 2016, Michael's total compensation was 4% salary and 96% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2023, Michael's direct individual holding has increased from 9.64m shares to 10.65m. Company insiders have collectively sold CA$545k more than they bought, via options and on-market transactions in the last 12 months.공시 • Dec 15Cronos Group Inc. Announces Launch of Its Highly Anticipated Lord Jones Live Resin Vapes in Two Different Hardware OptionsCronos Group Inc. announced the launch of its highly anticipated Lord Jones Live Resin Vapes in two different hardware options. Crafted with the discerning cannabis consumer in mind, these products embody a commitment to excellence, offering an unmatched combination of curated strains, pure live resin, and elegant high-quality hardware. The live resin format offers consumers a multi-dimensional, true-to-plant experience. This format is well suited for discerning consumers looking to level-up their cannabis experience. These vapes feature consistent high potency, with THC levels exceeding 70%, and advanced hardware designed to optimize live resin consumption, preserving terpenes and preventing clogging. The lineup also features versatile sizing options, including a 0.5g trial size in the convenience of an all-in-one device and a 1g stock-up size as a 510-thread cartridge, catering to both enthusiasts and those new to the category. Lord Jones Live Resin Vape are available in the following formats: Lord Jones Purple Lemon Haze Live Resin Vapes; Designed to deliver a supremely elevated experience, with notes of zesty citrus, pleasant earthiness, and sharp and spicy pepper flavors; Sativa | THC: 72-78% Available in two hardware options that have been optimized for live resin usage: A unique sleek 0.5g all-in-one device; A high-quality 1g 510-thread cartridge; Lord Jones Deadhead OG Live Resin Vapes; designed to deliver a truly complex flavor experience with savory, spicy, and woody flavors; Indica | THC: 71-77% Available in two hardware options That have been optimized for live resin use: A unique sleek 0. 5g all-in-one devices will be available in Alberta, Manitoba, Ontario, Saskatchewan and Yukon in 2024. Lord Jones batteries will be available in Manitoba, Ontario, Saskatchewan andYukon by early 2024. Lord Jones batteries will been available in Manitoba, Ontario, Alberta, Ontario, Saskatchewan and YukON by early 2024.공시 • Nov 29Future Farmco Canada Inc. entered into an agreement to acquire Peace Naturals Project Inc. from Cronos Group Inc. (TSX:CRON) for CAD 23 million.Future Farmco Canada Inc. entered into an agreement to acquire Peace Naturals Project Inc. from Cronos Group Inc. (TSX:CRON) for CAD 23 million on November 26, 2023. The aggregate purchase price will be paid as CAD 0.1 million will be paid in trust within two business days of the date of the Sale Agreement (b) CAD 1 million will be paid in trust within five business days of the waiver or satisfactions of the Buyer’s Condition, the Seller’s Condition and the Lease Condition (each, as defined below) and (c) the balance of the aggregate purchase price will be paid at the closing. Closing is expected to occur on the first business day that falls 30 calendar days following the later of (i) the satisfaction or waiver of the Buyer’s Condition or (ii) the satisfaction or waiver of the Seller’s Condition.Breakeven Date Change • Nov 11Forecast to breakeven in 2025The 8 analysts covering Cronos Group expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 78% per year to 2024. The company is expected to make a profit of US$7.29m in 2025. Average annual earnings growth of 92% is required to achieve expected profit on schedule.Reported Earnings • Nov 10Third quarter 2023 earnings released: US$0.005 loss per share (vs US$0.098 loss in 3Q 2022)Third quarter 2023 results: US$0.005 loss per share (improved from US$0.098 loss in 3Q 2022). Revenue: US$24.8m (up 19% from 3Q 2022). Net loss: US$1.46m (loss narrowed 96% from 3Q 2022). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings.분석 기사 • Nov 09Companies Like Cronos Group (TSE:CRON) Are In A Position To Invest In GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...공시 • Nov 04Cronos Group Inc. Launches Its Cannabis Brand Lord Jones in the Canadian Adult-Use Cannabis MarketCronos Group Inc. announced that it has launched its award-winning cannabis brand Lord Jones® in the Canadian adult-use cannabis market. The Lord Jones® brand will build on its legacy of delivering premium quality cannabis products by returning to its roots with bold THC-focused product innovations. The first Lord Jones® product to launch in Canada are Lord Jones® Hash Fusions pre-rolls. The popularity of hash products and premium pre-rolls is increasing amongst adult consumers. Hash is currently the most popular solventless infusion and is the second most popular infusion overall in the pre-roll category. The Lord Jones® Hash Fusions pre-rolls go beyond delivering an elevated, true-to-plant consumption experience. These pre-rolls are crafted with an optimized ratio of premium high-potency flower and complementary solventless ice water hash, which preserves the buds’ natural terpenes, fitted with a reusable ceramic tip to help cool the smoke. This new product has been extensively researched and sensory tested to deliver a smoother experience featuring bold cannabis flavors. Lord Jones® Hash Fusions pre-rolls are available in the following formats: Lord Jones® Hash Fusions – White Tahoe OG Flower x White Tahoe OG Ice Water Hash; Indica | THC: 35 – 40% | 1x1g; Lord Jones® Hash Fusions – Cosmic Kush Flower x Platinum GMO Ice Water Hash; Hybrid | THC: 35 – 40%+| 1x1g.공시 • Oct 31Cronos Group Inc. Unveils Its New THCV Products: Spinach FEELZ™? Full TiltCronos Group Inc. announced the launch of two new THCV-infused products; Spinach FEELZ Full Tilt THCV vape and gummy. Cronos also plans to launch a THCV-infused pre-roll under the Spinach FEELZ brand, which will add an additional offering under its robust and growing pre-roll portfolio. The Full Tilt THCV lineup is designed to give adult consumers an exciting new cannabis experience. The Spinach FEELZ full Tilt product range includes: Spinach FEELZ FullTilt Blue Razz Durban 7:1 THC|THCV vape; 700mg of THC and 100mg of THCV per 1g cartridge; Spinach FEELZ fullTilt Blue Raspberry Lemonade 1:2 THC|THCV gummies; 5 pieces/pack with 10mg of THC and 20mg THCV per pack. The THCV vape is now available in Alberta, British Columbia, and Ontario and the THCV edibles are available now in Ontario and British Columbia and will be available in Alberta by November 30. THC infused pre-rolls are planned for launch in 2024. Through Spinach FEELZ, Cronos is committed to bringing a full line of products featuring rare cannabinoids to consumers in a wide range of product formats. Each product is designed to deliver unique and enhanced experiences made possible through proprietary blends of rare cannabinoids alongside more well-known cannabinoids, like THC and CBD. Each product is formulated to help adult consumers, "Feelz. The Way You want." With a passion to responsibly elevate the consumer experience, Cronos is building an iconic brand portfolio. Cronos' diverse international brand portfolio includes Spinach®?, PEACE NATURALS®? and Lord Jones®?.Major Estimate Revision • Aug 15Consensus revenue estimates decrease by 14%, EPS upgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from US$95.4m to US$82.1m. EPS estimate increased from -US$0.127 to -US$0.118 per share. Pharmaceuticals industry in Canada expected to see average net income growth of 5.9% next year. Consensus price target broadly unchanged at CA$3.37. Share price fell 6.0% to CA$2.33 over the past week.공시 • Aug 10Cronos Group Inc. Revises Earnings Guidance for the Full Year 2023Cronos Group Inc. revised earnings guidance for the full year 2023. For the year, the company has decided to discontinue providing net revenue guidance and to withdraw previously announced net revenue target of $100 million to $110 million for full-year 2023. The discontinuance of providing net revenue guidance reflects turbulent market conditions beyond previous expectations in the markets in which Company operate, specifically, increasing political unrest and stagnant patient growth in Israel, the decision to exit the U.S. business, and competitive activity in Canada. In addition, foreign exchange rates have had unfavorable impact on Company's net revenue.Reported Earnings • Aug 08Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behindSecond quarter 2023 results: US$0.013 loss per share (improved from US$0.054 loss in 2Q 2022). Revenue: US$19.0m (down 18% from 2Q 2022). Net loss: US$5.53m (loss narrowed 73% from 2Q 2022). Revenue missed analyst estimates by 15%. Earnings per share (EPS) exceeded analyst estimates by 39%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has only fallen by 32% per year, which means it has not declined as severely as earnings.분석 기사 • Jul 17We're Hopeful That Cronos Group (TSE:CRON) Will Use Its Cash WiselyWe can readily understand why investors are attracted to unprofitable companies. For example, although...공시 • Jul 07Cronos Reportedly Explores Possible Sale After Attracting Takeover InterestCronos Group Inc. (TSX:CRON), the Canadian cannabis producer backed by cigarette maker Altria Group Inc. (MO.N), is exploring options that include a potential sale after attracting acquisition interest, people familiar with the matter said. Toronto-based Cronos is working with a financial adviser to handle the expressions of interest in a deal from other companies, including U.S.-based peer Curaleaf Holdings Inc. (CURA.CD), the sources said. The sources requested anonymity because the discussions are confidential, and they cautioned that no transaction is certain. Cronos and Curaleaf declined to comment. Spokespeople for Altria did not immediately respond to a request for comment.분석 기사 • Jun 20Cronos Group Inc.'s (TSE:CRON) Earnings Haven't Escaped The Attention Of InvestorsWhen you see that almost half of the companies in the Pharmaceuticals industry in Canada have price-to-sales ratios (or...공시 • May 20Cronos Group Inc. Announces Executive ChangesOn May 18, 2023, Cronos Group Inc. appointed James McGinness to the position of Vice President, Controller, which includes serving as the Company’s principal accounting officer, effective as of May 22, 2023. On May 18, 2023, the Company determined that Carlos Cortez, the Company’s Vice President, Controller, will no longer serve as the Company’s principal accounting officer as of May 22, 2023 and will separate from the Company, effective as of June 16, 2023. Prior to joining the Company, Mr. McGinness, age 45, was the Acting Chief Financial Officer and Vice President, Corporate Controller for MarketWise Inc. since April 2019. While at MarketWise, Mr. McGinness was responsible for the Accounting, Tax, External and Internal Financial Reporting, Investor Relations, and Financial Planning and Analysis functions and was instrumental in restructuring and developing a world-class finance organization while shepherding MarketWise through an Up-C SPAC transaction and several other strategic transactions. Prior to MarketWise, Mr. McGinness served as Corporate Controller at GSE Systems from August 2016 until November 2018 and previously held various management roles at Exelon, Washington Gas, T. Rowe Price and McCormick. Mr. McGinness is a CPA and earned a Bachelor of Science in Accounting from the State University of New York at Albany.Recent Insider Transactions Derivative • May 16President exercised options and sold CA$63k worth of stockOn the 11th of May, Michael Gorenstein exercised options to acquire 25k shares at no cost and sold these for an average price of CA$2.54 per share. This trade did not impact their existing holding. For the year to December 2016, Michael's total compensation was 4% salary and 96% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since September 2022, Michael's direct individual holding has increased from 9.47m shares to 10.62m. Company insiders have collectively bought CA$557k more than they sold, via options and on-market transactions, in the last 12 months.Major Estimate Revision • May 16Consensus EPS estimates upgraded to US$0.14 loss, revenue downgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from US$103.3m to US$99.7m. 2023 losses expected to reduce from -US$0.156 to -US$0.138 per share. Pharmaceuticals industry in Canada expected to see average net income decline 7.8% next year. Consensus price target down from CA$4.14 to CA$3.72. Share price fell 10% to CA$2.35 over the past week.Price Target Changed • May 15Price target decreased by 8.6% to CA$3.78Down from CA$4.14, the current price target is an average from 9 analysts. New target price is 63% above last closing price of CA$2.32. Stock is down 46% over the past year. The company is forecast to post a net loss per share of US$0.14 next year compared to a net loss per share of US$0.45 last year.공시 • May 10Cronos Group Inc. Provides Revenue Guidance for the Full Year 2023Cronos Group Inc. Provided revenue guidance for the full year 2023. For the year, the company expected to be between $100 million to $110 million.Reported Earnings • May 10First quarter 2023 earnings: EPS and revenues miss analyst expectationsFirst quarter 2023 results: US$0.10 loss per share. Revenue: US$20.1m (down 20% from 1Q 2022). Net loss: US$19.2m (loss narrowed 41% from 1Q 2022). Revenue missed analyst estimates by 19%. Earnings per share (EPS) also missed analyst estimates by 19%. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in Canada.Major Estimate Revision • Mar 07Consensus revenue estimates decrease by 11%, EPS upgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from US$114.3m to US$101.4m. EPS estimate increased from -US$0.175 to -US$0.155 per share. Pharmaceuticals industry in Canada expected to see average net income growth of 7.1% next year. Consensus price target down from CA$4.56 to CA$4.40. Share price fell 4.4% to CA$2.83 over the past week.매출 및 비용 세부 내역Cronos Group가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이TSX:CRON 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비31 Mar 26160-272531 Dec 25147-969430 Sep 251323671430 Jun 251301874431 Mar 251254976431 Dec 241184176430 Sep 24111-4874530 Jun 24102-5775531 Mar 2493-5477531 Dec 2387-7081630 Sep 2385-10187730 Jun 2381-13391831 Mar 2384-145931131 Dec 2287-1551011330 Sep 2291-2131091730 Jun 2291-1021302131 Mar 2285-2631452231 Dec 2165-1271222230 Sep 2166-3731542430 Jun 2157-3811422231 Mar 2151-3101322131 Dec 2047-721302030 Sep 20371011261930 Jun 20316361161731 Mar 20299291071631 Dec 19241,1671161230 Sep 19211,08965830 Jun 191847946531 Mar 191329332331 Dec 1812-2124230 Sep 189-815030 Jun 187-111031 Mar 185-29031 Dec 173-17030 Sep 17416030 Jun 17205031 Mar 171-14031 Dec 160-13030 Sep 16202030 Jun 16201031 Mar 16311031 Dec 15201030 Sep 150-42030 Jun 15-1-420양질의 수익: CRON 은(는) 현재 수익성이 없습니다.이익 마진 증가: CRON는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: CRON는 수익성이 없지만 지난 5년 동안 연평균 58.9%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 CRON의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: CRON은 수익성이 없어 지난 해 수익 성장률을 Pharmaceuticals 업계(64.6%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: CRON는 현재 수익성이 없으므로 자본 수익률이 음수(0.45%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/20 18:51종가2026/05/20 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Cronos Group Inc.는 16명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Jesse PytlakATB Cormark Historical (Cormark Securities)Vahan AjamianBeacon Securities LimitedNadine SarwatBernstein13명의 분석가 더 보기
Reported Earnings • May 12First quarter 2026 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2026 results: EPS: US$0.037 (up from US$0.016 in 1Q 2025). Revenue: US$45.2m (up 40% from 1Q 2025). Net income: US$13.8m (up 125% from 1Q 2025). Profit margin: 30% (up from 19% in 1Q 2025). Revenue exceeded analyst estimates by 7.5%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 5.0% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 97% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Feb 27Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2025 results: US$0.02 loss per share (down from US$0.11 profit in FY 2024). Revenue: US$146.6m (up 25% from FY 2024). Net loss: US$9.45m (down 123% from profit in FY 2024). Revenue exceeded analyst estimates by 5.1%. Earnings per share (EPS) missed analyst estimates. Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 96% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Nov 06Third quarter 2025 earnings released: EPS: US$0.07 (vs US$0.022 in 3Q 2024)Third quarter 2025 results: EPS: US$0.07 (up from US$0.022 in 3Q 2024). Revenue: US$36.3m (up 6.1% from 3Q 2024). Net income: US$26.0m (up 211% from 3Q 2024). Profit margin: 71% (up from 24% in 3Q 2024). Revenue is forecast to grow 5.8% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 96% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 08Second quarter 2025 earnings: EPS misses analyst expectationsSecond quarter 2025 results: US$0.10 loss per share (further deteriorated from US$0.023 loss in 2Q 2024). Revenue: US$33.5m (up 21% from 2Q 2024). Net loss: US$39.7m (loss widened 354% from 2Q 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates. Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 80% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
Reported Earnings • May 09First quarter 2025 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2025 results: EPS: US$0.02 (up from US$0.006 loss in 1Q 2024). Revenue: US$32.3m (up 28% from 1Q 2024). Net income: US$6.12m (up US$8.36m from 1Q 2024). Profit margin: 19% (up from net loss in 1Q 2024). Revenue exceeded analyst estimates by 2.3%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 9.8% p.a. on average during the next 3 years, compared to a 9.2% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 76% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
Reported Earnings • Feb 28Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2024 results: EPS: US$0.11 (up from US$0.18 loss in FY 2023). Revenue: US$117.6m (up 35% from FY 2023). Net income: US$41.1m (up US$110.9m from FY 2023). Profit margin: 35% (up from net loss in FY 2023). Revenue missed analyst estimates by 2.0%. Earnings per share (EPS) exceeded analyst estimates. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
속보 • May 18Cronos Group Beats Q1 Forecasts With Global Growth and Announces $50 Million BuybackCronos Group reported first-quarter revenue and Adjusted EBITDA ahead of expectations, supported by strong international momentum and Canadian market share gains. The company’s Israeli operations reached a ninth consecutive quarter of record revenue, while its Spinach brand took the number one position in the Canadian vape market. Management authorized a new $50 million share buyback program, and one covering analyst maintained a Buy rating with a C$5.00 price target. The key takeaway is that Cronos is pairing operating progress in core markets like Israel and Canada with capital allocation moves such as buybacks. Together, these developments indicate a focus on both growth and shareholder returns. Investors should still weigh execution risks in international markets and the usual uncertainties around cannabis regulation when assessing how durable these trends may be.
Reported Earnings • May 12First quarter 2026 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2026 results: EPS: US$0.037 (up from US$0.016 in 1Q 2025). Revenue: US$45.2m (up 40% from 1Q 2025). Net income: US$13.8m (up 125% from 1Q 2025). Profit margin: 30% (up from 19% in 1Q 2025). Revenue exceeded analyst estimates by 7.5%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 5.0% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 97% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.
내러티브 업데이트 • May 12CRON: Partial Rescheduling And Brand Execution Will Shape Lean Profit OutlookAnalysts have lifted their fair value estimate for Cronos Group from CA$3.19 to CA$3.45, citing recent initiation with a CA$4.50 price target and the view that branded positioning, a lean cost base, and potentially favorable regulatory shifts could support higher long term profitability and a lower future P/E assumption. Analyst Commentary Recent commentary around Cronos Group has focused on brand strength, cost discipline, and the potential impact of regulatory changes in key markets.
공시 • May 08Cronos Group Inc. Expands Pre-Roll Portfolio With Spinach STIXCronos Group Inc. announced that Spinach STIX, its latest innovation in its popular line-up of Spinach pre-rolls, is now available in more provinces across Canada. Spinach STIX is the brand’s first cylindrical-style pre-roll, designed to meet surging consumer interest in this highly sought-after format in the pre-roll category. The pre-roll category remains one of the largest and most popular in the Canadian cannabis market, accounting for more than 33% of national retail dollar sales. Nationally, the demand for cylindrical-style pre-rolls, which represented more than $17 million in Canadian retail sales in the pre-roll category in March 2026, is driven by consumer demand for pre-rolls that deliver a portable and compact design, an even and consistent burn, and a balanced, smooth smoking experience. Spinach STIX are available in the following curated selection of Cronos’ top-performing strains: Spinach STIX GMO Cookies, featuring sweet and savory flavor notes, Indica, THC: 25%+, 10x0.4g; Spinach STIX Sour Chem, featuring classic gasoline, chemical, and zesty citrus notes, Sativa, THC: 26%+, 10x0.4g; Spinach STIX Space Cake, featuring berry, nutty, and citrusy flavors, Hybrid, THC: 24%+, 10x0.4g. Spinach STIX pre-rolls are available now in Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland, Nova Scotia, Ontario, and Saskatchewan.
내러티브 업데이트 • Apr 25CRON: Partial Rescheduling Hopes Will Test Lean Cost Base ExecutionAnalysts have raised their Cronos Group price target to CA$4.50, citing expectations for slightly stronger revenue growth, modestly better profit margins, and a lower assumed future P/E, following recent bullish coverage and a favorable view on partial cannabis rescheduling. Analyst Commentary Recent research coverage on Cronos Group has centered on how potential regulatory shifts and brand positioning could influence the company’s path to improved profitability and valuation.
내러티브 업데이트 • Apr 11CRON: Canadian Brand Strength And Lean Cost Base Will Support Future UpsideAnalysts have reset their price target for Cronos Group to CA$4.50, reflecting fresh coverage that highlights the company’s established Canadian brands, its focus on scaling revenue with a lean cost base, and cultivation practices that are expected to support profitability trends. Analyst Commentary Recent coverage frames Cronos Group as a company with established Canadian brands and a focus on keeping its cost base lean while scaling revenue.
공시 • Mar 30Cronos Group Inc., Annual General Meeting, Jun 18, 2026Cronos Group Inc., Annual General Meeting, Jun 18, 2026.
내러티브 업데이트 • Mar 28CRON: Lean Cost Base And Brand Execution Will Shape Future Earnings PotentialAnalysts have lifted their average price target for Cronos Group to CA$4.50, citing expectations for faster top line expansion, a leaner cost base and stronger profitability potential supported by the company's established Canadian cannabis brands and cultivation practices. Analyst Commentary Recent Street research has framed Cronos Group as a branded cannabis operator with established products in Canada and an emphasis on scaling revenue while keeping operating costs in check.
내러티브 업데이트 • Mar 13CRON: Canadian Brand Strength And Rescheduling Shift Will Support Future UpsideAnalysts have lifted their CA$ price target on Cronos Group, citing the company's Canadian cannabis brands, expectations for better profitability as revenue grows against a lean cost base, and confidence in its cultivation practices as key supports for the higher valuation range. Analyst Commentary Bullish Takeaways Bullish analysts highlight Cronos Group's portfolio of Canadian cannabis brands as a key support for the higher CA$ valuation range, arguing that strong consumer recognition can help sustain revenue as the company scales.
Recent Insider Transactions Derivative • Mar 12President exercised options and sold CA$451k worth of stockOn the 8th of March, Michael Gorenstein exercised options to acquire 129k shares at no cost and sold these for an average price of CA$3.50 per share. This trade did not impact their existing holding. For the year to December 2019, Michael's total compensation was 19% salary and 81% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2025, Michael's direct individual holding has increased from 12.51m shares to 12.81m. Company insiders have collectively sold CA$4.7m more than they bought, via options and on-market transactions in the last 12 months.
Reported Earnings • Feb 27Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2025 results: US$0.02 loss per share (down from US$0.11 profit in FY 2024). Revenue: US$146.6m (up 25% from FY 2024). Net loss: US$9.45m (down 123% from profit in FY 2024). Revenue exceeded analyst estimates by 5.1%. Earnings per share (EPS) missed analyst estimates. Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 96% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.
내러티브 업데이트 • Feb 27CRON: Canadian Brand Strength And Rescheduling Shift Will Reshape Risk Reward ProfileAnalysts have lifted their fair value estimate for Cronos Group to CA$4.24 from CA$3.95, pointing to higher assumed revenue growth and a lower future P/E multiple. They are factoring in recent bullish coverage highlighting the company’s established Canadian cannabis brands, lean cost base, and cultivation practices.
Price Target Changed • Feb 24Price target increased by 7.2% to CA$4.24Up from CA$3.95, the current price target is an average from 4 analysts. New target price is 13% above last closing price of CA$3.74. Stock is up 39% over the past year. The company is forecast to post a net loss per share of US$0.0034 compared to earnings per share of US$0.11 last year.
공시 • Feb 17Cronos Group Inc. Launches New All-In-One Vape, Spinach PUFFERZCronos Group Inc. announced the launch of its newest all-in-one (AIO) vape, Spinach PUFFERZ. The latest innovation under Cronos' Spinach®? brand brings together high-quality cannabis infused with liquid diamonds in a convenient all-in-one device. Crafted for modern cannabis consumers who value functionality and design, Spinach PUFFERZ™? offers a seamless way to enjoy high-quality cannabis vape extracts and bold flavors. Every design element was carefully considered to deliver a differentiated experience. Spinach PUafferZ™? is Cronos' first AIO vape featuring the increasingly popular palm-style hardware. The device boasts a uniquely satisfying squish grip with a puffy exterior, a dual ceramic coil for maximum flavor and smooth draws, a boost button for temperature control, and a battery meter to indicate when a charge is needed. Spinach PUFFERZ™, the.
내러티브 업데이트 • Feb 13CRON: Rescheduling Shift Will Expose Execution Risks And Restrain Earnings UpsideAnalysts have lifted their CA$ fair value estimate for Cronos Group to CA$3.19, citing Street research that points to slightly higher expected revenue growth, modestly stronger profit margins, and a marginally lower future P/E assumption that together support a more constructive long term outlook. Analyst Commentary While the higher CA$3.19 fair value estimate reflects a more constructive stance on Cronos Group, not all research is leaning in the same direction.
공시 • Feb 03Cronos Group Launches Premium Lord Jones Brand in Israel, Advancing Borderless Product StrategyCronos Group Inc. announced the launch of its Lord Jones premium cannabis brand in Israel. The introduction marks a significant milestone in Cronos' borderless product strategy, expanding the Company's globally recognized brand portfolio into one of the most advanced and discerning medical cannabis markets in the world. The first phase of the launch brings five premium indoor-grown flower strains to Israeli patients. Lord Jones, established in North America for its refined brand identity and elevated craftsmanship, now enters the Israeli medical market with a focus on meeting the needs of medical patients. The brand's expansion into Israel underscores Cronos' commitment to thoughtful international growth driven by disciplined execution and differentiated brand experiences. In addition to the core flower offering, Cronos plans to expand the Lord Jones brand in Israel with future special edition and limited-run products. Lord Jones products are now available in pharmacies across Israel.
내러티브 업데이트 • Jan 30CRON: Rescheduling Shift And Product Expansion Will Shape A Balanced Earnings OutlookAnalysts have raised their price target on Cronos Group by a small amount to reflect updated assumptions for slightly higher revenue growth, a modestly stronger profit margin, and a marginally higher future P/E multiple. Analyst Commentary While some research points to a constructive view on Cronos Group, bearish analysts highlight a set of risks that could limit upside and keep the stock more range bound.
Major Estimate Revision • Jan 16Consensus EPS estimates fall from profit to US$0.005 lossThe consensus outlook for fiscal year 2025 has been updated. Expected to report loss instead of -US$0.005 instead of US$0.0205 per share profit previously forecast. Revenue forecast unchanged at US$137.9m Pharmaceuticals industry in Canada expected to see average net income growth of 40% next year. Consensus price target up from CA$3.95 to CA$4.10. Share price fell 5.4% to CA$3.53 over the past week.
내러티브 업데이트 • Jan 16CRON: Rescheduling Policy Shift Will Temper Optimism On Future Earnings ProfileAnalysts have raised their price target for Cronos Group to US$3.19 from US$2.90, pointing to updated assumptions around slightly higher discount rates, more conservative revenue growth and a modestly stronger profit margin profile, alongside a similar forward P/E outlook. What's in the News President Trump directed the Attorney General to complete the rulemaking process to reschedule marijuana to Schedule III of the Controlled Substances Act, which directly touches U.S. cannabis policy and mentions Cronos Group among other publicly traded peers in the sector (Marijuana Herald).
Recent Insider Transactions Derivative • Dec 17President exercised options and sold CA$293k worth of stockOn the 13th of December, Michael Gorenstein exercised options to acquire 65k shares at no cost and sold these for an average price of CA$4.51 per share. This trade did not impact their existing holding. For the year to December 2018, Michael's total compensation was 19% salary and 81% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2025, Michael has owned 12.51m shares directly. Company insiders have collectively sold CA$4.5m more than they bought, via options and on-market transactions in the last 12 months.
분석 기사 • Dec 13Cronos Group Inc. (TSE:CRON) Stock Rockets 29% As Investors Are Less Pessimistic Than ExpectedCronos Group Inc. ( TSE:CRON ) shareholders have had their patience rewarded with a 29% share price jump in the last...
Valuation Update With 7 Day Price Move • Dec 12Investor sentiment improves as stock rises 29%After last week's 29% share price gain to CA$4.48, the stock trades at a forward P/E ratio of 50x. Average trailing P/E is 14x in the Pharmaceuticals industry in Canada. Total returns to shareholders of 15% over the past three years.
공시 • Dec 10Cronos Group Inc. (TSX:CRON) entered into a definitive share sale and purchase agreement to acquire CanAdelaar B.V. from Ring International Holding AG and Landewyck Tobacco S.A.Cronos Group Inc. (TSX:CRON) entered into a definitive share sale and purchase agreement to acquire CanAdelaar B.V. from Ring International Holding AG and Landewyck Tobacco S.A. on December 9, 2025. The total consideration for the transaction is structured as follows: The base amount is €57.5 million. This amount will be adjusted by the net indebtedness, where a positive cash balance will increase the total, and a negative sum will decrease it. Additionally, €0.13 million, referred to as the "Sellers W&I Premium Amount," will be subtracted. Furthermore, 50% of any additional underwriting fees incurred by the purchaser up to completion, specifically related to additional due diligence aimed at lifting certain exclusions currently included in the W&I Policy, will be added to the total consideration. The consideration includes an additional contingent payment, payable in cash, based on 0.5 times CanAdelaar’s normalized EBITDA for the years 2026 and 2027. For the period ending September 30, 2025, CanAdelaar B.V. reported total revenue of €40.34 million and EBITDA of €24.05 million. The transaction is subject to approval by regulatory board / committee and approval of offer by acquirer board. The deal has been unanimously approved by the board. The expected completion of the transaction is January 1, 2026 to June 30, 2026.
공시 • Nov 25Cronos Group Inc. Launches Premium Lord Jones Live Resin Fusions in CanadaCronos Group Inc. announced is expanding its portfolio for its Lord Jones®? brand with new innovations designed to enhance its lineup of premium cannabis products in the Canadian market. The new Lord Jones Live Resin Fusions™? pre-rolls combine top-tier craftsmanship with exceptional cannabis genetics, reflecting the brand's continued dedication to quality and refinement. The Lord Jones Live Resin Fusion™? are carefully curated, pairing single-sourced dried flower with complementary, terpene-rich pure live resin caviar to deliver a delicious, flavor-forward, and differentiated smoking experience. Designed with an optimal ratio of live resin caviar-to-flower, each 0.5g pre-roll ensures a consistently smooth burn and high potency of 42%+ THC. Every pre-roll is fitted with a reusable ceramic tip, which cools the smoke for an even smoother, elevated experience. The Lord Jones Live Res in Fusions are now available in the following new strains: Lord Jones Live Resin F Fusion™? Durban Kush x Citrus Sap; Lord Jones Live Resin F intr™? Hell Fire OG x Cali Gas; Lord Jones Live ResinFusions™? Sour Diesel X Orange Velvet. New Lord Jones Live Resin F infusion™? are now available at select retailers across Canada.
Reported Earnings • Nov 06Third quarter 2025 earnings released: EPS: US$0.07 (vs US$0.022 in 3Q 2024)Third quarter 2025 results: EPS: US$0.07 (up from US$0.022 in 3Q 2024). Revenue: US$36.3m (up 6.1% from 3Q 2024). Net income: US$26.0m (up 211% from 3Q 2024). Profit margin: 71% (up from 24% in 3Q 2024). Revenue is forecast to grow 5.8% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 96% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
공시 • Oct 28Cronos Group Inc. Brings Back Popular, Limited-Edition Spinach Green Apple-Flavored Products for the Fall SeasonCronos Group Inc. announced that it is welcoming back its limited-edition Caramel Green Apple flavor to its best-selling lineup of SOURZ by Spinach edibles for the fall and Halloween season. The return of this popular and limited-edition product, which features buttery, sweet caramel and tart-green apple flavors and is perfect for the autumn months, follows its successful launch in Fall 2024. In addition to bringing back the original SOURZ by Spinach Caramel Green Apple 5-pack of gummies, Cronos is expanding its Fall season exclusive offerings with two new products: SOURZ by Spinach Fully Blasted Caramel Green Apple 10mg THC gummy; Spinach Sweet Green Apple 1g vape (Sativa): Infused with liquid diamonds and featuring crisp green apple flavor notes. These limited-time, seasonal Spinach products are available now across Canada.
공시 • Oct 09Cronos Group Inc. Launches Sourz by Spinach Fully Blasted MultipacksCronos Group Inc. announced that its popular SOURZ by Spinach Fully Blasted gummies will now be available in new multipack formats. The SOURZ by Spinach fully Blasted Multipacks with liquid diamond-infused gummies are now available in five of its most popular flavors, offering consumers more choice, convenience, and value when purchasing Canada's favorite cannabis edible. SOURZ by Spinach Fully Blasted Multipacks with Liquid diamond-infused gummies will be available in 5- and 10-packs in the following flavors: 10-Pack (10 x 10mg THC gummies): SOURZ by Spinach Fully Blasted Blue Raspberry Watermelon gummies; SOURZ by Spinach Fully Blasted Pink Lemonade gummies; SOUR Z by Spinach FullyBlasted Strawberry Mango gummies: SOURZ by spinach Fully Blasted Peach Orange gummies; 5-Pack (5 x 10mg THC gummies); SOURZ by Spinach- Fully Blasted Blue Raspberry Water Watermelon gummies; SourZ by Spinach fully Blasted Pink Lemonade gibles; SOURZ by SpinACH Fully Blasted Strawberry Mango gummies; SOURZ By Spinach Fully Blasting Peach Orange gummies; 5 -Pack (5 x 10mgTH gummies); SOURZ By Spinach Fully Blasting Peach Orange Gummies; 5-Pack (5 x 10mg THC gummies; SOURZby Spinach Fully Blast Blue Raspberry Watermelon gummies and SOURZ by Spinach? Fully Blasted Pink Lemonades gummies. The SOURZ by spinach Fully Blasted Multipack with liquid diamond-infused Gummies are available now in Alberta, British Columbia, Manitoba, Newfoundland, Nova Scotia, Ontario, Prince Edward Island, and Saskatchewan.
Valuation Update With 7 Day Price Move • Sep 29Investor sentiment improves as stock rises 16%After last week's 16% share price gain to CA$4.13, the stock trades at a forward P/E ratio of 109x. Average trailing P/E is 34x in the Pharmaceuticals industry in Canada. Total returns to shareholders of 3.0% over the past three years.
내러티브 업데이트 • Sep 04GrowCo Capacity And Global Markets Will Unlock PotentialThe Consensus Analyst Price Target for Cronos Group has increased to CA$3.95, primarily reflecting a notable rise in the company's Future P/E multiple despite stable revenue growth expectations. What's in the News President Trump is considering reclassifying marijuana as a less dangerous drug, which could ease restrictions and benefit cannabis companies such as Cronos Group (The Wall Street Journal).
Price Target Changed • Sep 03Price target increased by 10% to CA$3.95Up from CA$3.59, the current price target is an average from 2 analysts. New target price is 14% above last closing price of CA$3.48. Stock is up 17% over the past year. The company is forecast to post a net loss per share of US$0.015 compared to earnings per share of US$0.11 last year.
분석 기사 • Aug 15Cronos Group Inc.'s (TSE:CRON) 26% Share Price Surge Not Quite Adding UpCronos Group Inc. ( TSE:CRON ) shareholders would be excited to see that the share price has had a great month, posting...
Reported Earnings • Aug 08Second quarter 2025 earnings: EPS misses analyst expectationsSecond quarter 2025 results: US$0.10 loss per share (further deteriorated from US$0.023 loss in 2Q 2024). Revenue: US$33.5m (up 21% from 2Q 2024). Net loss: US$39.7m (loss widened 354% from 2Q 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates. Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 80% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
공시 • Aug 07Cronos Group Inc. Appoints Lloyd Wilson as the Principal Accounting Officer, Effective as of August 7, 2025Cronos Group Inc. Appointed Lloyd Wilson, Vice President, Controller, as the Company’s principal accounting officer, effective as of August 7, 2025. Lloyd is a seasoned financial leader and licensed Chartered Public Accountant with over 20 years of experience in financial reporting, internal audit, plant controllership, and operational finance. With a strong background in consumer-packaged goods and previous experience as a plant controller, Lloyd most recently served as a Corporate Controller, where he oversaw financial reporting, internal controls, and policy implementation.
Price Target Changed • Jul 09Price target increased by 14% to CA$4.08Up from CA$3.59, the current price target is an average from 3 analysts. New target price is 43% above last closing price of CA$2.85. Stock is down 9.2% over the past year. The company is forecast to post a net loss per share of US$0.061 compared to earnings per share of US$0.11 last year.
Major Estimate Revision • Jul 02Consensus EPS estimates fall by 254%, revenue upgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast increased from US$146.6m to US$149.5m. Forecast EPS reduced from -US$0.017 to -US$0.061 per share. Pharmaceuticals industry in Canada expected to see average net income growth of 34% next year. Consensus price target of CA$3.77 unchanged from last update. Share price was steady at CA$2.61 over the past week.
Major Estimate Revision • May 15Consensus EPS estimates have been downgraded.The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from US$149.2m to US$145.5m. Now expected to report a loss of US$0.006 per share instead of US$0.0074 per share profit previously forecast. Pharmaceuticals industry in Canada expected to see average net income growth of 38% next year. Consensus price target of CA$3.48 unchanged from last update. Share price rose 5.0% to CA$2.92 over the past week.
Reported Earnings • May 09First quarter 2025 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2025 results: EPS: US$0.02 (up from US$0.006 loss in 1Q 2024). Revenue: US$32.3m (up 28% from 1Q 2024). Net income: US$6.12m (up US$8.36m from 1Q 2024). Profit margin: 19% (up from net loss in 1Q 2024). Revenue exceeded analyst estimates by 2.3%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 9.8% p.a. on average during the next 3 years, compared to a 9.2% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 76% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
공시 • May 09Cronos Group Inc. (TSX:CRON) announces an Equity Buyback for 19,270,951 shares, representing 5% for $50 million.Cronos Group Inc. (TSX:CRON) announces a share repurchase program. Under the program, the company will repurchase up to 19,270,951 shares representing 5% of it's issued share for $50 million. The repurchases will be made from available funds. The repurchase program is valid till May 13, 2026.
새로운 내러티브 • Apr 30GrowCo Expansion Will Boost Operations But Strain Cash Flow Investment in GrowCo and advancements in cannabis genetics are set to improve efficiency, enhance profitability, and strengthen market penetration.
공시 • Apr 23Cronos Group Inc. Unveils New Spinach 1.2g Vapes and SOURZ by Spinach Gummies Enhanced with Rare CannabinoidsCronos Group Inc.'s best-selling cannabis brand, Spinach®?, introduced three all-new 1.2g vape products, each expertly crafted with premium THC and enhanced with rare cannabinoids for a uniquely elevated experience. Along with these innovative vape offerings, Cronos is also unveiling new SOURZ by Spinach®? Fully Blasted flavors, infused with rare cannabinoids. The new lineup includes three new 1.2 gram vapes in the following formats: Mango Kiwi Haze CBC (Sativa): A refreshing, uplifting blend with a 1:10 CBC-to-THC ratio. Peach Passionfruit Kush CBN (Indica): A dreamy, restful experience with a 1:10 CBN-to-THC ratio; Strawberry Watermelon OG CBG (Hybrid): A blissful, relaxed high with a 1:10 CBG-to-THC ratio.; Designed for consumers who prioritize both potency and added value, these vapes deliver 1,000mg of THC without compromising on the unique benefits of rare cannabinoids. Each product features winterized, distilled cannabis extract for purity, combined with terpene-rich flavors inspired by renowned cultivars. All Spinach®? vapes are crafted with ceramic heaters, stainless steel components, and food-grade materials to ensure quality and a smooth experience. In addition to the Spinach®? vape launch, Cronos is expanding its best-selling edible line, SOURZ by Spinach™?, with the new Fully Blasted lineup with each package containing one 10mg THC gummy in bold, fruit-forward flavors: Mango Lime: Tropical mango and tangy lime flavors with 10mg CBC and 10mg THC per gummy.
공시 • Mar 28Cronos Group Inc., Annual General Meeting, Jun 20, 2025Cronos Group Inc., Annual General Meeting, Jun 20, 2025.
Recent Insider Transactions Derivative • Mar 26President exercised options and sold CA$3.1m worth of stockOn the 21st of March, Michael Gorenstein exercised options to acquire 1m shares at no cost and sold these for an average price of CA$2.61 per share. This trade did not impact their existing holding. For the year to December 2018, Michael's total compensation was 21% salary and 79% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2024, Michael's direct individual holding has increased from 11.09m shares to 11.68m. Company insiders have collectively sold CA$4.4m more than they bought, via options and on-market transactions in the last 12 months.
공시 • Mar 20Cronos Group Inc. Announces Chief Financial Officer ChangesCronos Group Inc. announced the appointment of Anna Shlimak as Chief Financial Officer, effective March 19, 2025. Ms. Shlimak, who previously served as Cronos’ Chief Strategy Officer, will succeed James Holm who is stepping down to pursue other opportunities and will remain with the Company through April 18, 2025 to ensure a seamless transition. Ms. Shlimak has been an integral part of Cronos’ leadership team for the last seven years, playing a key role in shaping the Company’s strategy, operational efficiencies, and engagement with the financial and investment community. During her tenure, she has led many strategic initiatives including cost optimization, revenue growth, and building Cronos’ corporate brand, which have positioned the Company for long-term success. Anna recently served as the Company’s Chief Strategy Officer and was responsible for managing and directing the organization’s corporate strategy, investor relations, communications, government affairs, and information systems departments. Prior to joining Cronos, Anna was the Head of Investor Relations at Quest Partners LLC, a research-driven alternative investment firm. Anna was responsible for business development, investor reporting, marketing, and communication initiatives for the fund. Before that, Anna held a range of roles at the New York Stock Exchange in both the New York and London offices. She received a Master of Business Administration from Columbia Business School and holds a Bachelor of Science in Economics from The Wharton School at the University of Pennsylvania.
Recent Insider Transactions Derivative • Mar 19President exercised options and sold CA$306k worth of stockOn the 15th of March, Michael Gorenstein exercised options to acquire 112k shares at no cost and sold these for an average price of CA$2.72 per share. This trade did not impact their existing holding. For the year to December 2018, Michael's total compensation was 21% salary and 79% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2024, Michael's direct individual holding has decreased from 11.09m shares to 10.45m. Company insiders have collectively sold CA$1.3m more than they bought, via options and on-market transactions in the last 12 months.
Recent Insider Transactions Derivative • Mar 12President exercised options and sold CA$230k worth of stockOn the 8th of March, Michael Gorenstein exercised options to acquire 80k shares at no cost and sold these for an average price of CA$2.86 per share. This trade did not impact their existing holding. For the year to December 2018, Michael's total compensation was 21% salary and 79% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2024, Michael's direct individual holding has decreased from 11.09m shares to 10.20m. Company insiders have collectively sold CA$1.2m more than they bought, via options and on-market transactions in the last 12 months.
Reported Earnings • Feb 28Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2024 results: EPS: US$0.11 (up from US$0.18 loss in FY 2023). Revenue: US$117.6m (up 35% from FY 2023). Net income: US$41.1m (up US$110.9m from FY 2023). Profit margin: 35% (up from net loss in FY 2023). Revenue missed analyst estimates by 2.0%. Earnings per share (EPS) exceeded analyst estimates. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
Recent Insider Transactions Derivative • Dec 17President exercised options and sold CA$183k worth of stockOn the 13th of December, Michael Gorenstein exercised options to acquire 66k shares at no cost and sold these for an average price of CA$2.79 per share. This trade did not impact their existing holding. For the year to December 2017, Michael's total compensation was 21% salary and 79% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2024, Michael has owned 11.09m shares directly. Company insiders have collectively sold CA$826k more than they bought, via options and on-market transactions in the last 12 months.
Breakeven Date Change • Dec 05Forecast to breakeven in 2025The 3 analysts covering Cronos Group expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 82% to 2024. The company is expected to make a profit of US$10.2m in 2025. Average annual earnings growth of 95% is required to achieve expected profit on schedule.
Reported Earnings • Nov 14Third quarter 2024 earnings: EPS and revenues exceed analyst expectationsThird quarter 2024 results: EPS: US$0.02 (up from US$0.004 loss in 3Q 2023). Revenue: US$34.3m (up 38% from 3Q 2023). Net income: US$8.35m (up US$9.81m from 3Q 2023). Profit margin: 24% (up from net loss in 3Q 2023). Revenue exceeded analyst estimates by 13%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 3.6% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.
Major Estimate Revision • Nov 13Consensus revenue estimates increase by 12%, EPS downgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast increased from US$107.8m to US$120.7m. EPS estimate fell from -US$0.072 to -US$0.086 per share. Pharmaceuticals industry in Canada expected to see average net income growth of 51% next year. Consensus price target of CA$3.44 unchanged from last update. Share price was steady at CA$3.15 over the past week.
Major Estimate Revision • Oct 01Consensus EPS estimates upgraded to US$0.074 lossThe consensus outlook for fiscal year 2024 has been updated. 2024 losses forecast to reduce from -US$0.083 to -US$0.074 per share. Revenue forecast unchanged from US$111.3m at last update. Pharmaceuticals industry in Canada expected to see average net income growth of 55% next year. Consensus price target of CA$3.51 unchanged from last update. Share price was steady at CA$2.87 over the past week.
공시 • Aug 28Cronos Group Inc. Announces Lord Jones Live Resin Vapes and Ice Water Hash Pre-Rolls Now Available Across CanadaCronos Group Inc. is expanding its portfolio for its Lord Jones brand with new innovations to bolster its lineup of premium cannabis products in the Canadian market. The additions include new cultivars for the Lord Jones Ice Water Hash Fusions Pre-Rolls and Live Resin Vapes, which are now available across Canada. The Lord Jones Ice Water Hash Fusions Pre-Rolls and Live Resin Vapes are now available in the following new flavors and sizes: Lord Jones Ice Water Hash Fusions Pre-Rolls: Sour Blueberry x Sour Blueberry. 1g ice water hash flower pre-roll with blueberry and gas flavor notes. Indica | THC: 35-41% | 1x1g. Snow Lotus x Animal Mints. 1g ice water hash flower pre-roll with sweet, minty, and spicy flavor notes. Hybrid | THC: 35-41% | 1x1g Lord Jones Live Resin Vapes (All-in-One and 510-Cartridge): Gorilla Z Live Resin Vape A flavor-forward vape designed to boast an promoted berry, cherry, and grape flavor experience. Hybrid | 70+% THC . Available in two hardware options that are optimized for live resin usage: A sleek 0.5g all-in-one device. A high-quality 1g 510-thread cartridge.
Breakeven Date Change • Aug 12No longer forecast to breakevenThe 7 analysts covering Cronos Group no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$1.46m in 2025. New consensus forecast suggests the company will make a loss of US$6.32m in 2026.
Reported Earnings • Aug 09Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behindSecond quarter 2024 results: US$0.02 loss per share (further deteriorated from US$0.015 loss in 2Q 2023). Revenue: US$27.8m (up 46% from 2Q 2023). Net loss: US$8.76m (loss widened 59% from 2Q 2023). Revenue exceeded analyst estimates by 7.2%. Earnings per share (EPS) missed analyst estimates. Revenue is forecast to grow 7.2% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.
Major Estimate Revision • Jul 12Consensus EPS estimates fall by 10%The consensus outlook for fiscal year 2024 has been updated. 2024 expected loss increased from -US$0.042 to -US$0.046 per share. Revenue forecast unchanged at US$103.7m. Pharmaceuticals industry in Canada expected to see average net income growth of 54% next year. Consensus price target of CA$3.61 unchanged from last update. Share price rose 6.5% to CA$3.26 over the past week.
Breakeven Date Change • Jul 11No longer forecast to breakevenThe 7 analysts covering Cronos Group no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$5.69m in 2025. New consensus forecast suggests the company will make a loss of US$6.12m in 2026.
Major Estimate Revision • Jul 01Consensus EPS estimates fall by 93%The consensus outlook for fiscal year 2024 has been updated. 2024 expected loss increased from -US$0.022 to -US$0.042 per share. Revenue forecast of US$103.3m unchanged since last update. Pharmaceuticals industry in Canada expected to see average net income growth of 56% next year. Consensus price target down from CA$3.74 to CA$3.61. Share price was steady at CA$3.19 over the past week.
공시 • Jun 28Cronos Group Inc. Brand Spinach®? Celebrates Summer with New LaunchesCronos Group Inc.'s Spinach®? brand is expanding its portfolio of award-winning and best-selling cannabis products just in time for the summer months. Summer innovations feature new flavors and formats from Cronos' SOURZ by Spinach®? edibles and a premier milled flower product. The new SOURZ by Spinach™? Fully Blasted gummies offer the same great-tasting SOURZ by Spinach ®? flavors, now with 10 mg of THC per piece. The SOURZ by SpinACH®? Tropical Party Pack introduces new gummies with bolder tropical flavors, in the distinctive Spinach®? "S" shape. These gummies have a perfect blend of sour and sweet and utilize Cronos' proprietary flavor-masking technology. SOURZ by SpinachTM Fully Blasted includes one 10 mg THC gummy per package in the following flavors: Pink Lemonade; Sweet and refreshing flavors of raspberry and lemonade; Blue Raspberry Watermelon; Electric blue raspberry and refreshing watermelon; Cherry Lime; Delightful cherry and tangy lime. SOURZ by SpinACH™? Tropical Party Pack: 1 mg THC per gummy, 10 mg THC per pack; Featuring three new dual-flavors: Peach Passionfruit, Pineapple Coconut, and Strawberry Guava. Additionally, the Spinach®? brand will introduce Spinach®?, milled flower options designed to be ready to use for joints or vaporizers. Ready-to-use milled flower offerings have grown in popularity in the Canadian cannabis market, appealing to value-conscious consumers seeking convenience. Spinach Grindz™? caters to this growing demand by providing high-quality, milled cannabis that saves time and effort, allowing consumers to enjoy a consistent and hassle-free cannabis experience. Spinach Grindz®? are now available in the following strains: Citrus Crush; Milled flower with citrus, sour, and earthy notes; Cookie Dough; Milled flower with sweet, nutty, and creamy notes.
공시 • Jun 22Cronos Group Inc. Elects Murray Garnick as DirectorCronos Group Inc. at its Annual Meeting of Shareholders held on June 20, 2024, approved to elect Murray Garnick as director.
분석 기사 • May 31We're Interested To See How Cronos Group (TSE:CRON) Uses Its Cash Hoard To GrowEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Breakeven Date Change • May 12Forecast breakeven date moved forward to 2025The 8 analysts covering Cronos Group previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 87% to 2024. The company is expected to make a profit of US$5.67m in 2025. Average annual earnings growth of 62% is required to achieve expected profit on schedule.
Reported Earnings • May 10First quarter 2024 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2024 results: US$0.01 loss per share (improved from US$0.05 loss in 1Q 2023). Revenue: US$25.3m (up 26% from 1Q 2023). Net loss: US$2.24m (loss narrowed 88% from 1Q 2023). Revenue exceeded analyst estimates by 7.0%. Earnings per share (EPS) also surpassed analyst estimates by 1.9%. Revenue is forecast to grow 8.7% p.a. on average during the next 3 years, compared to a 9.1% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.
Major Estimate Revision • May 07Consensus EPS estimates upgraded to US$0.036 lossThe consensus outlook for fiscal year 2024 has been updated. 2024 losses forecast to reduce from -US$0.045 to -US$0.036 per share. Revenue forecast steady at US$99.8m. Pharmaceuticals industry in Canada expected to see average net income growth of 49% next year. Consensus price target of CA$3.57 unchanged from last update. Share price fell 10% to CA$3.63 over the past week.
Breakeven Date Change • May 07No longer forecast to breakevenThe 7 analysts covering Cronos Group no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$1.72m in 2026. New consensus forecast suggests the company will make a loss of US$4.06m in 2026.
Major Estimate Revision • Apr 16Consensus EPS estimates fall by 24%The consensus outlook for fiscal year 2024 has been updated. 2024 expected loss increased from -US$0.036 to -US$0.045 per share. Revenue forecast of US$100.9m unchanged since last update. Pharmaceuticals industry in Canada expected to see average net income growth of 50% next year. Consensus price target of CA$3.57 unchanged from last update. Share price fell 7.2% to CA$3.36 over the past week.
분석 기사 • Apr 01Cronos Group Inc.'s (TSE:CRON) P/S Is Still On The Mark Following 29% Share Price BounceThe Cronos Group Inc. ( TSE:CRON ) share price has done very well over the last month, posting an excellent gain of...
공시 • Mar 28Cronos Group Inc., Annual General Meeting, Jun 20, 2024Cronos Group Inc., Annual General Meeting, Jun 20, 2024.
Major Estimate Revision • Mar 26Consensus EPS estimates upgraded to US$0.037 lossThe consensus outlook for fiscal year 2024 has been updated. 2024 losses forecast to reduce from -US$0.046 to -US$0.037 per share. Revenue forecast steady at US$100.9m. Pharmaceuticals industry in Canada expected to see average net income growth of 56% next year. Consensus price target of CA$3.46 unchanged from last update. Share price rose 17% to CA$3.62 over the past week.
공시 • Mar 26Cronos Group Inc. Launches Lord Jones Chocolate FusionsCronos Group Inc. announced the launch of Lord Jones Chocolate Fusions, its exciting first entry into the chocolate edibles category. Cronos' newest edible innovation was developed and designed by an expert team of culinary chefs, food scientists, and leaders in cannabis product development. The bite-sized Chocolate Fusions feature a dynamic, multi- texture experience, combining a soft and chewy center, crunch inclusions, and an outer layer of rich creamy chocolate that delivers a decadent sweet treat for adult cannabis consumers. Lord Jones Chocolate Fusions feature winning attributes to attract cannabis consumers, including three delicious flavor combinations, an artisanal design that highlights a creative combination of textures, and a flavor-masking system to ensure outstanding taste. Through an extensive research and sensory testing process, team of experts seized the opportunity to deliver an exceptional edible that elevates the overall category. Each package of Lord Jones Chocolate Fusions includes five pieces with 2mg of THC per piece. Chocolate Fusions will be available in the following flavors and formats: Lord Jones Cookies & Cream Chocolate Fusions, 10mg THC total per package, Three layers of white chocolate, cookie crunch bits, and a chewy fudge center, Lord Jones Salted Caramel Crunch 1:1 CBD | THC Chocolate Fusions, 10mg CBD per package, 10mg THC and 10mg CBD per package, Three layers of milk chocolate, a sweet and salty crunch, and a smooth caramel center, Lord Jones Dazzleberry Pop Chocolate Fusions, 10mgTH total per package, Three layers the gold-dusted dark chocolate, a crackling pop, and a sweet berry center. Cronos continues to be an award-winning leader in cannabis edibles. The same team behind the hugely popular SOURZ by Spinach® and Spinach FEELZTM portfolio of gummies leveraged their expertise in the edibles space to create this innovation for the chocolate category for the Lord Jones® brand.
Recent Insider Transactions Derivative • Mar 20President exercised options and sold CA$232k worth of stockOn the 15th of March, Michael Gorenstein exercised options to acquire 87k shares at no cost and sold these for an average price of CA$2.68 per share. This trade did not impact their existing holding. For the year to December 2017, Michael's total compensation was 4% salary and 96% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2023, Michael's direct individual holding has increased from 9.64m shares to 9.83m. Company insiders have collectively sold CA$963k more than they bought, via options and on-market transactions in the last 12 months.
Reported Earnings • Mar 03Full year 2023 earnings: EPS and revenues miss analyst expectationsFull year 2023 results: US$0.18 loss per share (improved from US$0.45 loss in FY 2022). Revenue: US$87.2m (down 5.1% from FY 2022). Net loss: US$69.8m (loss narrowed 59% from FY 2022). Revenue missed analyst estimates by 1.6%. Earnings per share (EPS) also missed analyst estimates by 101%. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings.
분석 기사 • Mar 02We Think Cronos Group (TSE:CRON) Can Afford To Drive Business GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Major Estimate Revision • Mar 02Consensus EPS estimates fall by 44%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from US$109.2m to US$102.2m. Losses expected to increase from US$0.03 per share to US$0.043. Pharmaceuticals industry in Canada expected to see average net income growth of 63% next year. Consensus price target of CA$3.49 unchanged from last update. Share price fell 9.2% to CA$2.75 over the past week.
분석 기사 • Feb 02Revenues Tell The Story For Cronos Group Inc. (TSE:CRON)When you see that almost half of the companies in the Pharmaceuticals industry in Canada have price-to-sales ratios (or...
Breakeven Date Change • Dec 31Forecast to breakeven in 2026The 8 analysts covering Cronos Group expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$236.3k in 2026. Average annual earnings growth of 68% is required to achieve expected profit on schedule.
Recent Insider Transactions Derivative • Dec 17President exercised options and sold CA$169k worth of stockOn the 13th of December, Michael Gorenstein exercised options to acquire 66k shares at no cost and sold these for an average price of CA$2.58 per share. This trade did not impact their existing holding. For the year to December 2016, Michael's total compensation was 4% salary and 96% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2023, Michael's direct individual holding has increased from 9.64m shares to 10.65m. Company insiders have collectively sold CA$545k more than they bought, via options and on-market transactions in the last 12 months.
공시 • Dec 15Cronos Group Inc. Announces Launch of Its Highly Anticipated Lord Jones Live Resin Vapes in Two Different Hardware OptionsCronos Group Inc. announced the launch of its highly anticipated Lord Jones Live Resin Vapes in two different hardware options. Crafted with the discerning cannabis consumer in mind, these products embody a commitment to excellence, offering an unmatched combination of curated strains, pure live resin, and elegant high-quality hardware. The live resin format offers consumers a multi-dimensional, true-to-plant experience. This format is well suited for discerning consumers looking to level-up their cannabis experience. These vapes feature consistent high potency, with THC levels exceeding 70%, and advanced hardware designed to optimize live resin consumption, preserving terpenes and preventing clogging. The lineup also features versatile sizing options, including a 0.5g trial size in the convenience of an all-in-one device and a 1g stock-up size as a 510-thread cartridge, catering to both enthusiasts and those new to the category. Lord Jones Live Resin Vape are available in the following formats: Lord Jones Purple Lemon Haze Live Resin Vapes; Designed to deliver a supremely elevated experience, with notes of zesty citrus, pleasant earthiness, and sharp and spicy pepper flavors; Sativa | THC: 72-78% Available in two hardware options that have been optimized for live resin usage: A unique sleek 0.5g all-in-one device; A high-quality 1g 510-thread cartridge; Lord Jones Deadhead OG Live Resin Vapes; designed to deliver a truly complex flavor experience with savory, spicy, and woody flavors; Indica | THC: 71-77% Available in two hardware options That have been optimized for live resin use: A unique sleek 0. 5g all-in-one devices will be available in Alberta, Manitoba, Ontario, Saskatchewan and Yukon in 2024. Lord Jones batteries will be available in Manitoba, Ontario, Saskatchewan andYukon by early 2024. Lord Jones batteries will been available in Manitoba, Ontario, Alberta, Ontario, Saskatchewan and YukON by early 2024.
공시 • Nov 29Future Farmco Canada Inc. entered into an agreement to acquire Peace Naturals Project Inc. from Cronos Group Inc. (TSX:CRON) for CAD 23 million.Future Farmco Canada Inc. entered into an agreement to acquire Peace Naturals Project Inc. from Cronos Group Inc. (TSX:CRON) for CAD 23 million on November 26, 2023. The aggregate purchase price will be paid as CAD 0.1 million will be paid in trust within two business days of the date of the Sale Agreement (b) CAD 1 million will be paid in trust within five business days of the waiver or satisfactions of the Buyer’s Condition, the Seller’s Condition and the Lease Condition (each, as defined below) and (c) the balance of the aggregate purchase price will be paid at the closing. Closing is expected to occur on the first business day that falls 30 calendar days following the later of (i) the satisfaction or waiver of the Buyer’s Condition or (ii) the satisfaction or waiver of the Seller’s Condition.
Breakeven Date Change • Nov 11Forecast to breakeven in 2025The 8 analysts covering Cronos Group expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 78% per year to 2024. The company is expected to make a profit of US$7.29m in 2025. Average annual earnings growth of 92% is required to achieve expected profit on schedule.
Reported Earnings • Nov 10Third quarter 2023 earnings released: US$0.005 loss per share (vs US$0.098 loss in 3Q 2022)Third quarter 2023 results: US$0.005 loss per share (improved from US$0.098 loss in 3Q 2022). Revenue: US$24.8m (up 19% from 3Q 2022). Net loss: US$1.46m (loss narrowed 96% from 3Q 2022). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings.
분석 기사 • Nov 09Companies Like Cronos Group (TSE:CRON) Are In A Position To Invest In GrowthEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
공시 • Nov 04Cronos Group Inc. Launches Its Cannabis Brand Lord Jones in the Canadian Adult-Use Cannabis MarketCronos Group Inc. announced that it has launched its award-winning cannabis brand Lord Jones® in the Canadian adult-use cannabis market. The Lord Jones® brand will build on its legacy of delivering premium quality cannabis products by returning to its roots with bold THC-focused product innovations. The first Lord Jones® product to launch in Canada are Lord Jones® Hash Fusions pre-rolls. The popularity of hash products and premium pre-rolls is increasing amongst adult consumers. Hash is currently the most popular solventless infusion and is the second most popular infusion overall in the pre-roll category. The Lord Jones® Hash Fusions pre-rolls go beyond delivering an elevated, true-to-plant consumption experience. These pre-rolls are crafted with an optimized ratio of premium high-potency flower and complementary solventless ice water hash, which preserves the buds’ natural terpenes, fitted with a reusable ceramic tip to help cool the smoke. This new product has been extensively researched and sensory tested to deliver a smoother experience featuring bold cannabis flavors. Lord Jones® Hash Fusions pre-rolls are available in the following formats: Lord Jones® Hash Fusions – White Tahoe OG Flower x White Tahoe OG Ice Water Hash; Indica | THC: 35 – 40% | 1x1g; Lord Jones® Hash Fusions – Cosmic Kush Flower x Platinum GMO Ice Water Hash; Hybrid | THC: 35 – 40%+| 1x1g.
공시 • Oct 31Cronos Group Inc. Unveils Its New THCV Products: Spinach FEELZ™? Full TiltCronos Group Inc. announced the launch of two new THCV-infused products; Spinach FEELZ Full Tilt THCV vape and gummy. Cronos also plans to launch a THCV-infused pre-roll under the Spinach FEELZ brand, which will add an additional offering under its robust and growing pre-roll portfolio. The Full Tilt THCV lineup is designed to give adult consumers an exciting new cannabis experience. The Spinach FEELZ full Tilt product range includes: Spinach FEELZ FullTilt Blue Razz Durban 7:1 THC|THCV vape; 700mg of THC and 100mg of THCV per 1g cartridge; Spinach FEELZ fullTilt Blue Raspberry Lemonade 1:2 THC|THCV gummies; 5 pieces/pack with 10mg of THC and 20mg THCV per pack. The THCV vape is now available in Alberta, British Columbia, and Ontario and the THCV edibles are available now in Ontario and British Columbia and will be available in Alberta by November 30. THC infused pre-rolls are planned for launch in 2024. Through Spinach FEELZ, Cronos is committed to bringing a full line of products featuring rare cannabinoids to consumers in a wide range of product formats. Each product is designed to deliver unique and enhanced experiences made possible through proprietary blends of rare cannabinoids alongside more well-known cannabinoids, like THC and CBD. Each product is formulated to help adult consumers, "Feelz. The Way You want." With a passion to responsibly elevate the consumer experience, Cronos is building an iconic brand portfolio. Cronos' diverse international brand portfolio includes Spinach®?, PEACE NATURALS®? and Lord Jones®?.
Major Estimate Revision • Aug 15Consensus revenue estimates decrease by 14%, EPS upgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from US$95.4m to US$82.1m. EPS estimate increased from -US$0.127 to -US$0.118 per share. Pharmaceuticals industry in Canada expected to see average net income growth of 5.9% next year. Consensus price target broadly unchanged at CA$3.37. Share price fell 6.0% to CA$2.33 over the past week.
공시 • Aug 10Cronos Group Inc. Revises Earnings Guidance for the Full Year 2023Cronos Group Inc. revised earnings guidance for the full year 2023. For the year, the company has decided to discontinue providing net revenue guidance and to withdraw previously announced net revenue target of $100 million to $110 million for full-year 2023. The discontinuance of providing net revenue guidance reflects turbulent market conditions beyond previous expectations in the markets in which Company operate, specifically, increasing political unrest and stagnant patient growth in Israel, the decision to exit the U.S. business, and competitive activity in Canada. In addition, foreign exchange rates have had unfavorable impact on Company's net revenue.
Reported Earnings • Aug 08Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behindSecond quarter 2023 results: US$0.013 loss per share (improved from US$0.054 loss in 2Q 2022). Revenue: US$19.0m (down 18% from 2Q 2022). Net loss: US$5.53m (loss narrowed 73% from 2Q 2022). Revenue missed analyst estimates by 15%. Earnings per share (EPS) exceeded analyst estimates by 39%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has only fallen by 32% per year, which means it has not declined as severely as earnings.
분석 기사 • Jul 17We're Hopeful That Cronos Group (TSE:CRON) Will Use Its Cash WiselyWe can readily understand why investors are attracted to unprofitable companies. For example, although...
공시 • Jul 07Cronos Reportedly Explores Possible Sale After Attracting Takeover InterestCronos Group Inc. (TSX:CRON), the Canadian cannabis producer backed by cigarette maker Altria Group Inc. (MO.N), is exploring options that include a potential sale after attracting acquisition interest, people familiar with the matter said. Toronto-based Cronos is working with a financial adviser to handle the expressions of interest in a deal from other companies, including U.S.-based peer Curaleaf Holdings Inc. (CURA.CD), the sources said. The sources requested anonymity because the discussions are confidential, and they cautioned that no transaction is certain. Cronos and Curaleaf declined to comment. Spokespeople for Altria did not immediately respond to a request for comment.
분석 기사 • Jun 20Cronos Group Inc.'s (TSE:CRON) Earnings Haven't Escaped The Attention Of InvestorsWhen you see that almost half of the companies in the Pharmaceuticals industry in Canada have price-to-sales ratios (or...
공시 • May 20Cronos Group Inc. Announces Executive ChangesOn May 18, 2023, Cronos Group Inc. appointed James McGinness to the position of Vice President, Controller, which includes serving as the Company’s principal accounting officer, effective as of May 22, 2023. On May 18, 2023, the Company determined that Carlos Cortez, the Company’s Vice President, Controller, will no longer serve as the Company’s principal accounting officer as of May 22, 2023 and will separate from the Company, effective as of June 16, 2023. Prior to joining the Company, Mr. McGinness, age 45, was the Acting Chief Financial Officer and Vice President, Corporate Controller for MarketWise Inc. since April 2019. While at MarketWise, Mr. McGinness was responsible for the Accounting, Tax, External and Internal Financial Reporting, Investor Relations, and Financial Planning and Analysis functions and was instrumental in restructuring and developing a world-class finance organization while shepherding MarketWise through an Up-C SPAC transaction and several other strategic transactions. Prior to MarketWise, Mr. McGinness served as Corporate Controller at GSE Systems from August 2016 until November 2018 and previously held various management roles at Exelon, Washington Gas, T. Rowe Price and McCormick. Mr. McGinness is a CPA and earned a Bachelor of Science in Accounting from the State University of New York at Albany.
Recent Insider Transactions Derivative • May 16President exercised options and sold CA$63k worth of stockOn the 11th of May, Michael Gorenstein exercised options to acquire 25k shares at no cost and sold these for an average price of CA$2.54 per share. This trade did not impact their existing holding. For the year to December 2016, Michael's total compensation was 4% salary and 96% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since September 2022, Michael's direct individual holding has increased from 9.47m shares to 10.62m. Company insiders have collectively bought CA$557k more than they sold, via options and on-market transactions, in the last 12 months.
Major Estimate Revision • May 16Consensus EPS estimates upgraded to US$0.14 loss, revenue downgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from US$103.3m to US$99.7m. 2023 losses expected to reduce from -US$0.156 to -US$0.138 per share. Pharmaceuticals industry in Canada expected to see average net income decline 7.8% next year. Consensus price target down from CA$4.14 to CA$3.72. Share price fell 10% to CA$2.35 over the past week.
Price Target Changed • May 15Price target decreased by 8.6% to CA$3.78Down from CA$4.14, the current price target is an average from 9 analysts. New target price is 63% above last closing price of CA$2.32. Stock is down 46% over the past year. The company is forecast to post a net loss per share of US$0.14 next year compared to a net loss per share of US$0.45 last year.
공시 • May 10Cronos Group Inc. Provides Revenue Guidance for the Full Year 2023Cronos Group Inc. Provided revenue guidance for the full year 2023. For the year, the company expected to be between $100 million to $110 million.
Reported Earnings • May 10First quarter 2023 earnings: EPS and revenues miss analyst expectationsFirst quarter 2023 results: US$0.10 loss per share. Revenue: US$20.1m (down 20% from 1Q 2022). Net loss: US$19.2m (loss narrowed 41% from 1Q 2022). Revenue missed analyst estimates by 19%. Earnings per share (EPS) also missed analyst estimates by 19%. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in Canada.
Major Estimate Revision • Mar 07Consensus revenue estimates decrease by 11%, EPS upgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from US$114.3m to US$101.4m. EPS estimate increased from -US$0.175 to -US$0.155 per share. Pharmaceuticals industry in Canada expected to see average net income growth of 7.1% next year. Consensus price target down from CA$4.56 to CA$4.40. Share price fell 4.4% to CA$2.83 over the past week.
